Zusammenfassung
Schilddrüsenerkrankungen gehören zu den Volkskrankheiten mit einer hohen Prävalenz in der Bevölkerung. Neue Erkenntnisse auf zellulärer Ebene führen zu einem besseren Verständnis der pathophysiologischen Zusammenhänge. Molekularbiologische Untersuchungen haben das Spektrum der Diagnostik von benignen und malignen Erkrankungen erweitert.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur Kap. 2
Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, Rago T, Grasso L, Valeriano R, Balestrieri A, Pinchera A (1999) The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 84:561–566
Bauch K (1998) Epidemiology of functional autonomy. Exp Clin Endocrinol Diabetes 106 Suppl 4:S16–22
Berglund J, Christensen, SB, Hallengren B (1990) Total and age-specific incidence of Graves’ thyrotoxicosis, toxic nodular goitre and solitary toxic adenoma in Malmö, 1970–1974. J Intern Med 227 137–141
Bjoro T, Holmen J, Krüger O, Midthjel, K, Hunstad K, Schreiner T, Sandnes L, Brochmann H (2000) Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The health study of Nord-Trondelag (HUNT). Eur J Endocrinol 143:639–647
Brabant G, Prank K, Ranft U, Schuermeyer T, Wagner TO, Hauser H, Kummer B, Feistner H, Hesch RD, von zur Mühlen A (1990) Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. J Clin Endocrinol Metab 70:403–409
Brand OJ, Barrett JC, Simmonds MJ, Newby PR, McCabe CJ, Bruce CK, Kysela B et al. (2009) Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet 18:1704–13
Bryhni B, Aanderud S, Sundsfjord J, Rekvig OP, Jorde R (1996) Thyroid antibodies in northern Norway: prevalence, persistence and relevance. J Intern Med 239:517–523
Bürgi H (2010) Iodide excess. Best Pract Res Clin Endocrinol Metab 24:107–15. Review
Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Laurberg P (2011) Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol 164:801–809
Chiamolera MI, Wondisford FE (2009) Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology 150:1091–1096
Davies TF, Yin X, Latif R (2010) The genetics of the thyroid stimulating hormone receptor: history and relevance. Thyroid 20:727–36. Review
Feldkamp J. Autoimmunthyreoiditis. (2009) Diagnose und Therapie. Dtsch Med Wochenschr 134:2504–2509
Fujiwara H, Tatsumi K, Miki K, Harada T, Miyai K, Takai S, Amino N (1997) Congenital hypothyroidism caused by a mutation in the Na+/I– symporter Nature Gen. 16:124–125
Gärtner R, Dugrillon A (1998) Vom Jodmangel zur Struma – Pathophysiologie der Jodmangelstruma. Internist 39:566–573
Gereben B, Zavacki A, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A, Bianco AC (2008) Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling. Endocr Rev. 2008 29: 898–938
Gesundheitsberichterstattung des Bundes, Robert Koch Institut 2011
Gnidehou S, Caillou B, Talbot M, Ohayon R, Kaniewski J, Noel-Hudson MS, Morand S, Agnangji D, Sezan A, Courtin F, Virion A, Dupuy C (2004) Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site. FASEB J 18: 1574–1576
Hegedüs L, Bonnema SJ, Bennedbaek FN (2003) Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 24:102–132
Höppner W, Ritter M (2002) in: Feldkamp J, Scott M, Scherbaum WA: Medulläres Schilddrüsenkarzinom. de Gruyter, Berlin New York, S 3–15
Kahaly GJ, Dietlein M, Gärtner R, Mann K, Dralle H (2007) Amiodaron und Schilddrüsendysfunktion. Dtsch Ärztebl 104(51–52): A-3550/B-3129/C-3021
Köhrle J, Brabant G (2010) Synthese, Transport und Stoffwechsel der Schilddrüsenhormone. Der Internist 51:559–567
Kopp P, Kimura ET, Aeschimann S, Oestreicher M, Tobler A, Fey MF, Studer H (1994) Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 79:134–139
Krohn K, Führer D, Holzapfel HP, Paschke R (1998) Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 83:130–134
Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter. Endocr Rev. 26: 504–524
Lan L, Cui D, Nowka K, Derwahl M (2007) Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes J Clin Endocrinol Metab 92: 3681–3688
Meng W, Scriba P (2002) Jodversorgung in Deutschland. Probleme und erforderliche Maßnahmen: Update 2002. Dtsch Ärzteblatt 99:A2560–A2564
Morreale de Escobar G, Obregon MF Escobar del Rey (2004) Role of thyroid hormone during early brain development. Eur J Endocrinol 151 Suppl 3:U25–37
Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010 22:475–85. Review
Patel J, Landers K, Li H, Mortimer RH, Richard K (2011) Delivery of maternal thyroid hormones to the fetus. Trends Endocrinol Metab 22:164–70
Rendl J, Juhran N, Reiners C (2001) Thyroid volumes and urinary iodine in German school children. Exp Clin Endocrinol Diabetes 109:8–12
Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, Schumm-Draeger PM (2004) Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 14:926–932
Ringold DA, Nicoloff JT, Kesler M, Davis H, Hamilton A, Mack T (2002) Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid 12:647–53
Schmid KW (2010) Molekularpathologie von Schilddrüsentumoren. Pathologe [Suppl 2] 31:229–233
Thamm M, Ellert U, Liesenkötter K-P, Völzke H (2007) Jodversorgung in Deutschland. Ergebnisse des Jodmonitorings im Kinder- und Jugendgesundheitssurvey. Bundesgesundhbl – Gesundheitsforsch –Gesundheitsschutz 50:744–749
Tomer Y (2010) Genetic Susceptibility to Autoimmune Thyroid Disease: Past, Present, and Future. Thyroid 20: 715–725
Völzke H, Lüdemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U, Meng W (2003) The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 13:803–10
Weetman AP (2009) The genetics of autoimmune disease thyroid thyroid disease. Horm Metab Res 2009 41:421–5 Review
Xing M (2007) BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocr Rev 28:742–762
Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660
Ferlito A, Robbins KT, Shah JP, Medina JE, Silver CE, Al-Tamimi S, Fagan JJ, Paleri V, Takes RP, Bradford CR, Devaney KO, Stoeckli SJ, Weber RS, Bradley PJ, Suárez C, Leemans CR, Coskun HH, Pitman KT, Shaha AR, de Bree R, Hartl DM, Haigentz M Jr, Rodrigo JP, Hamoir M, Khafif A, Langendijk JA, Owen RP, Sanabria A, Strojan P, Vander Poorten V, Werner JA, Bień S, Woolgar JA, Zbären P, Betka J, Folz BJ, Genden EM, Talmi YP, Strome M, González Botas JH, Olofsson J, Kowalski LP, Holmes JD, Hisa Y, Rinaldo A (2011) Proposal for a rational classification of neck dissections. Head Neck 33(3):445–50
Lanz T von, Wachsmuth W (1955) Die Schilddrüse. In: Lanz T von, Wachsmuth W (Hrsg) Praktische Anatomie, 1. Band, 2. Teil „Hals“. Springer, Berlin Göttingen Heidelberg
Lenquist S, Cahlin C, Smeds S (1987) The superior laryngeal nerve in thyroid surgery. Surgery 102:999
Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA (2008) Committee for Neck Dissection Classification, American Head and Neck Society Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 134(5):536–8. Review
Seiler CA, Wagner HE (1994) The non-recurrent inferior laryngeal nerve. An important rarity in thyroid gland surgery. Chirurg 65:358
Whitfield P, Morton RP, Al-Ali S (2010) Surgical anatomy of the external branch of the superior laryngeal nerve. ANZ J Surg 80(11):813–6
Amino N, Tada H, Hidaka Y (1999) Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Thyroid 9: 705–713
Baloch ZW, Puttaswamy K, Brose M, LiVolsi VA (2006) Lack of BRAF mutations in hyalinizing trabecular neoplasm. Cytojournal 3:17
Carney JA, Hirokawa M, Lloyd RV et al. (2008) Hyalinizing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol 32:1877–1889
Carney JA, Ryan J, Goellner JR (1987) Hyalinizing trabecular adenoma of the thyroid gland. Am J Surg Pathol 11: 583–91
Chazenbalk GD, Pichurin P, Chen CR, Latrofa F, Johnstone AP, McLachlan SM et al. (2002) Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest 110: 209–217
Cheung CC, Boerner SL, MacMillan CM et al (2000) Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24:1622–1626
Collins J, Gough S (2002) Autoimmunity in thyroid disease. Eur J Nucl Med Mol Imaging 29 Suppl 2: S417–S424
Dahlgren M, Khosroshahi A, Nielson GP, Deshpande V, Stone JH (2010) Riedel’s Thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arth Care Res 62: 1312–1318
Fagin JA (2002) Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16:903–911
Fonseca E, Nesland JM, Sobrinho-Simoes M (1997) Expression of stratified epithelial-type cytokeratins in hyalinizing trabecular adenomas supports their relationship with papillary carcinomas of the thyroid. Histopathology 31:330–335
Ghossein RA, Rosai J, Heffess C (1997) Dyshormonogenetic Goiter: A Clinicopathologic Study of 56 Cases. Endocr Pathol 8: 283–292
Grüters-Kieslich A, Karges W, Schmid KW (2011) Kongenitale Schilddrüsenerkrankungen. In: Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Brabant G, Karges W (Kapitelkoordinatoren). Thieme, Stuttgart New York, Sonderauszugsausgabe Schilddrüsenerkrankungen pp 6–12
Harach HR, Williams ED (1990) The pathology of granulomatous diseases of the thyroid gland. Sarcoidosis 7:19–27
Kahaly G, Dralle H, Mann K, Reiners C (2011) Autoimmunthyreopathien. In: Brabant G, Karges W (Kapitelkoordinatoren) Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Thieme, Stuttgart New York, Sonderauszugsausgabe Schilddrüsenerkrankungen pp 12–22
Krause K, Führer D (2008) Molekulare Mechanismen der Schilddrüsentumorgenese. Der Nuklearmediziner 31: 209–215
Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26:504–524
Krohn K, Maier J, Paschke R (2007) Mechanisms of disease: Hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endocrinol Metab 3:713–720
McNicol AM, Lewis PD (1996) The thyroid gland. In: Lewis PD (ed) Systemic pathology, vol 12: The endocrine system. Churchill Livingstone, New York Edinburgh London Madrid Melbourne San Francisco Tokyo, pp 131–185
Molberg K, Albores-Saavedra J (1994) Hyalinizing trabecular carcinoma of the thyroid gland. Hum Pathol 25: 192-7. (1994) Hyalinizing trabecular carcinoma of the thyroid gland. Hum Pathol 25: 192–7
Musholt TJ, Clerici T, Dralle H, et al. (2011) German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 396:639–649
Ozdemir D, Dagdelen S, Erbas T (2010) Endocrine involvement in systemic amyloidosis. Endocr Pract 16:1056–1063
Papi G, LiVolsi V (2004) Current concepts on Riedel Thyreoiditis. Am J Clin Pathol 121 (Suppl 1): S50–S63
Paschke R, Brabant G, Dralle H, Reiners C (2011) Struma diffusa und Knotenstruma. In: Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Brabant G, Karges W (Kapitelkoordinatoren). Georg Thieme Verlag Stuttgart New York, Sonderauszugsausgabe Schilddrüsenerkrankungen pp 22–28
Quadbeck B, Eckstein AK, Tews S, Walz M, Hoermann R, Mann K et al. (2002) Maturation of thyroidal dendritic cells in Graves' disease. Scand J Immunol 55: 612–620
Rakover YT, Chertok Shacham E, Ishay A, Elmalah I, Joachim P (2012) Minimal Invasive Follicular Thyroid Carcinoma Developed in Dyshormonogenetic Multinodular Goiter Due to Thyroid Peroxidase Gene Mutation. Thyroid [Epub ahead of print]
Reiners C, Wegscheider K, Schicha H, et al. (2004) Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 14: 926–932
Reiners C, Paschke R, Mann K (2011) Funktionelle Autonomie. In: Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Brabant G, Karges W (Kapitelkoordinatoren). Georg Thieme Verlag Stuttgart New York, Sonderauszugsausgabe Schilddrüsenerkrankungen pp 28–30
Rosai J, Carcangiu M, DeLellis RA (1992) Tumors of the thyroid gland. In: Atlas of Tumor Pathology, Vol 5. AFIP, Washington/DC
Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard JA et al. (1995) Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 80: 1347–51
Salvatore G, Chiappetta G, Nikiforov YE et al (2005) Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. Eur J Cancer 41:816–821
Schmid KW (1993) Subacute granulomatous (deQuervain´s) thyroiditis. Am Soc Clin Pathol , Check Sample Continuing Education Program AP 93–7: 1–4
Schmid KW, Sheu SY, Görges R, Enzinger C, Tötsch M (2003) Tumoren der Schilddrüse. Pathologe 24:357–372
Sheu SY, Schmid KW (2003) Entzündungen der Schilddrüse. Pathologe 24:339–347
Sheu SY, Görges R, Schmid KW (2003) Hyperplasien der Schilddrüse. Pathologe 24:348–356
Sheu SY, Levin S, Schmid KW (2006) Therapiebedingte Veränderungen der Schilddrüse. Pathologe 27:13–18
Sheu SY, Vogel E, Worm K et al (2010) Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology 56:632–640
Ting S, Puttinger C, Schmid KW, Sheu SY (2012) Der hyalinisierender trabekuläre Tumor der Schilddrüse. Eine übertrieben vorsichtige Bezeichnung für einen gutartigen Tumor? Pathologe 33:135–141
Villa F, Dionigi G, Tanda ML, Rovera F, Boni L (2008) Amyloid goiter. Int J Surg 6 Suppl 1:S16–18
Weetman AP (2001) Determinants of autoimmune thyroid disease. Nat Immunol 2: 769–770
WHO histological classification of thyroid and parathyroid tumours (2004) In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs. IARC Press, Lyon, pp 49–123
Allahabadia A, Weetman AP (2003) Dynamic thyroid stimulating hormone tests: do they still have a role? J Endocrinol Invest 26:31–38. Review
Brabant G, Kahaly GJ Schicha, H, Reiners C (2006) Milde Formen der Schilddrüsenfehlfunktion: Ursachen, Diagnostik, Vorgehen. Dtsch Arztebl 103(31–32): A-2110
Demers LM, Spencer CA (2003) Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 58:138–140
Giovannini S, Zucchelli GC, Iervasi G, Iervasi A, Chiesa MR, Mercuri A, Renieri A, Prontera C, Conte R, Clerico A (2011) Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study. Clin Chem Lab Med 49:1669–1676
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499
Jones DD, May KE, Geraci SA (2010) Subclinical thyroid disease Am J Med 123:502–504 Review
Mebis L, Van den Berghe G (2011) Thyroid axis function and dysfunction in critical illness. Best Pract Res Clin Endocrinol Metab 25:745–757
Owen WE, Gantzer ML, Lyons JM, Rockwood AL, Roberts WL (2011) Functional sensitivity of seven automated thyroid stimulating hormone immunoassays. Clin Chim Acta 412:2336–2339
Petersenn S, Quabbe HJ, Schöfl C, Stalla GK, von Werder K, Buchfelder M (2010) Sinnvolle Hypophysenstimulationstests. Dtsch Arztebl Int 107:437–443
Surks MI, Goswami G, Daniels GH (2005) The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 90: 5489–5496
Völzke H, Ludemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U, Meng W (2003) The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 13: 803–810
WHO (1997) Recommended normative values for thyroid volume in children aged 6 15 years. World Health Organization and international Council for Control of lodine Deficiency Disorders. Bull World Health Organ 75: 95–7
Bojunga J, Herrmann E, Meyer G, Weber S, Zeuzem S, Friedrich-Rust M. (2010) Real-time elastography for the differentiation of benign and malignant thyroid nodules: a meta-analysis. Thyroid 20:1145–50
Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN (2005) Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237:794–800
Friedrich-Rust M, Romenski O, Meyer G, Dauth N, Holzer K, Grünwald F, Kriener S, Herrmann E, Zeuzem S, Bojunga J (2011) Acoustic Radiation Force Impulse-Imaging for the evaluation of the thyroid gland: A limited patient feasibility study. Ultrasonics 52:69–74
Horvath E, Majlis S, Ricardo Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M(2009) An Ultrasonogram Reporting System for Thyroid Nodules Stratifying Cancer Risk for Clinical Management. JCEM 2009 94:1748–1751
Papini E, Guglielmi R, Bianchini A, Crescenzi A,Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM (2002) Risk of Malignancy in Nonpalpable Thyroid Nodules: Predictive Value of Ultrasound and Color-Doppler Features. JCEM 87:1941–1946
Paschke R (2009) Abklärung des euthyreoten Schilddrüsenknotens: Wann punktieren? Stellenwert der Sonographie Dtsch Med Wochenschr 134:2498–2503
Rago T, Vitti P (2008) Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 22:913–28. Review
Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, Schumm-Dräger PM (2004) Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96 278 unselected employees. Thyroid 14:926–932
Saleh A, Santen R, Malms J, Feldkamp J, Fürst G, Scherbaum WA, Mödder U (1998) B-Mode-Sonographie und moderne dopplersonographische Methoden bei Krankheiten der Schilddrüse und der Nebenschilddrüsen. Radiologe 38:344–354
Saller B, Moeller L, Görges R, Janssen OE, Mann K (2002) Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 110:403–407
Sebag F, Vaillant-Lombard J, Berbis J, Griset V, Henry JF, Petit P, Oliver C (2010) Shear Wave Elastography: A New Ultrasound Imaging Mode for the Differential Diagnosis of Benign and Malignant Thyroid Nodules. JCEM 95:5281–5288
Zhang B, Jiang YX, Liu JB, Yang M, Dai Q, Zhu QL, Gao P (2010) Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid 20:51–7
Gotway M, Higgins C (2000) MR imaging of the thyroid and parathyroid glands. Magn Reson. Imaging Clin N Am 8:163–182
Kaplan S, Mandel S, Muller R et al. (2009) The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels. AJNR Am J Neuroradiol 30:608–612
Loevner L, Kaplan S, Cunnane M et al. (2008) Cross-sectional imaging of the thyroid gland. Neuroimaging Clin N Am 18:445–461
Nitz W., Balzer T, Grosu D, Allkemper T (2010) Principles of Magnetic Resonance. In: Reimer P, Parizel P, Meaney J, Stichnoth F (eds) Clinical MR Imaging, 3rd ed. Springer, Berlin Heidelberg New York, pp 1–106
Prokop M (2011) Grundlagen. In: Prokop M, Galanski M, Schaefer-Prokop C, Molen A van der (Hrsg) Gankörper-Computertomographie, 2. Aufl. Thieme, Stuttgart New York, S 2–50
Steger-Hartmann T, Hofmeister R, Ernst R et al. (2010) A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol 45:520–528
Weber A, Randolph G, Aksoy F (2000) The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am 38:1105–1129
Bähre M, Hilgers R, Lindemann C, Emrich D (1987) Physiological aspect of the thyroid trapping function and its suppression in iodine deficiency using 99mTc-pertechnetate. Acta Endocrinol 115:175–182
Brom M, Joosten L, Laverman P, Oyen WJ, Béhé M, Gotthardt M, Boerman OC (2011) Preclinical Evaluation of 68Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors. Mol Imaging 10(2):144–152
Campennì A, Violi MA, Ruggeri RM, Sindoni A, Moleti M, Vermiglio F, Baldari S (2010) Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. Nucl Med Commun 31(4):274–9
Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P (2004) Recombinant human thyrotropin stimulation of fluoro-D-oxy-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91–95
Davidson J, McDougall IR (2000) How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans? Eur J Nucl Med 27(4):425–430
Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H, Deutsche Gesellschaft für Nuklearmedizin, Deutsche Gesellschaft für Medizinische Physik (2007a) Verfahrensanweisung für die Schilddrüsenszintigraphie (Version 3). Nuklearmedizin 46(5):203–205
Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O; Deutsche Gesellschaft für Nuklearmedizin (2007b) Leitlinie zur Radioiodtherapie (RIT) bei benignen Schilddrüsenerkrankungen (Version 4). Nuklearmedizin 46(5):220–223
Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H, Deutsche Gesellschaft für Nuklearmedizin, Deutsche Gesellschaft für Medizinische Physik (2007c) Verfahrensanweisung zum Radioiodtest (Version 3). Nuklearmedizin 46(5):198–202
Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W (1995) 18FDG Ganzkörper-PET bei differenzierten Schilddrüsenkarzinomen – Flipflop im Speichermuster von 18FDG und 131J. Nuklearmedizin 34(4):127–34
Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, Muller SP, Bockisch A, Debatin JF, Brandau W (2004) Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092–2098
Freudenberg LS, Jentzen W, Lind T, Bockisch A, Görges R (2007a) Schilddrüsenkarzinome. In: Krause BJ, Schwaiger M, Buck K (Hrsg) Nuklearmedizinische Onkologie. Verlagsgruppe Hüthig Jehle Rehm GmbH, ecomed Medizin
Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A (2007b) 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46(4):121–128
Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ (2011) Clinical applications of (124)I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 12 (im Druck)
Gotthardt M, Stübinger M, Pansegrau J, Buchwald B, Goecke J, Pfestroff A, Corstens FH, Behr TM (2006) Decrease of 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970 s: clinical implications for radioiodine therapy. Nuklearmedizin 45:122–125
Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, Kim SW, Chung JH (2010) Localization of medullary thyroid carcinoma after surgery using 11 C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J 57(12):1045–1054
Joseph K (1995) Quantifizierte Schilddrüsenszintigraphie. Der Nuklearmediziner 18:228–236
Lassmann M, Luster M, Hänscheid H, Reiners C (2004) Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45:619–625
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM (2010) Clinical Value of 18–Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma. Thyroid 20(5):527–533
Mahlstedt J, Schmidt H, Joseph K (1979) Untersuchungen zur Verlässlichkeit der 99mTc-Speichertests als Schätzer der thyreoidalen Stimulation. Fortsch Röntgenstr 131:536–544
Bennebaek FN, Perrild H, Hegedüs L (1999) Diagnosis and treatment of the solitary thyroid nodule: results of a European survey. Clin Endocrinol (Oxf) 50:357–363
Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A (1998) Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 8:15–21
Dietmaier W, Hartmann A, Wallinger S et al. (1999) Multiple mutation analyses in single tumor cells enabled by improved whole genome amplification. Am J Pathol 154:83–95
Droese M (1995) Punktionszytologie der Schilddrüse, 2. Aufl. Schattauer, Stuttgart New York
Ersöz C, Firat P, Uguz A, Kuzey GM (2004) Fine-needle aspiration cytology of solitary thyroid nodules. Cancer Cytopathology 102:302–307
Gharib H (1994) Current evaluation of thyroid nodules. Trends Endocrinol Metab 5:365–369
Gharib H, Goellner (1993) Fine needle aspiration biopsy of the thyroid: an appraisal. Ann Int Med 118:282–289
Harms H, Hofmann M, Ruschenburg I (2002) Fine Needle Aspiration of the Thyroid. Can an Image Processing System Improve differentiation? Analyt Quant Cytol Histol 24:147–153
Hermus AR, Huysmans DA (1998) Treatment of benign nodular thyroid disease. New Engl J Med 338:1438–1447
Hofstädter F, Schullian W, Unterkircher S (1979) Die Feinnadelaspiration der Schilddrüse. Wien Klin Wochenschr 91:748–751
Karges W (2005) Klinische und molekulare Genetik des Schilddrüsenkarzinoms. Onkologe 11:20–28
Langsteger W, Költringer P, Buchinger W, Dominik K, Binter G, Eber O (1993) Epidemiological and etiological aspects in thyroid carcinoma. In: Pimpl W, Galvan G, Kogelnik HD, Manfreda D, Niederle B, Schlag P, Waclawiczek HW (eds) Struma maligna. Springer, Berlin Heidelberg New York Tokyo, S 3–11
Mandreker SRS, Nadkarni NS, Pinto RGW, Menezes S (1995) Role of fine needle aspiration cytology as the initial modality in the investigation of thyroid lesions. Acta Cytol 39:898–904
Mazzaferri (1993) Management of solitary thyroid nodule. N Engl J Med 328:553–559
McHenry CR, Walfish PG, Rosen IB (1993) Non-diagnostic fine needle aspiration biopsy: a dilemma in management of nodular thyroid disease. Am Surg 59:415–419
Rüschoff J, Hofstädter F (1997) Wertigkeit der Schilddrüsenpunktionszytologie zur Selektion verdächtiger Knoten. Onkologe 3:16–21
Suen K (1996) Guidelines of the Papanicolaou society of cytopathology of the examination of fine-needle aspiration specimens from thyroid nodules. Mod Pathol 9:710–715
Badillo J, Shimaoka K, Lessmann EM, Marchetta FC, Sokal JE (1963) Treatment of nontoxic goiter with sodium liothyronine. JAMA 184:151–158
Bennedbaek FN, Karstrup S, Hegedus L (1997) Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur J Endocrinol 136:240–250
Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL (1990) Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 336:193–197
Caraccio N, Goletti O, Lippolis PV, Casolaro A, Cavina E, Miccoli P, Monzani F (1997) Is percutaneous ethanol injection a useful alternative for the treatment of the cold benign thyroid nodule? Five years‘ experience. Thyroid 7:699–704
Celani MF (1993) Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. Exp Clin Endocrinol Diabetes 101:326–332
Celani MF, Mariani M, Mariani G (1990) On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. Acta Endocrinol (Copenh) 123:603–608
Cheung PS, Lee JM, Boey JH (1989) Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. World J Surg 13:818–822
Cooper DS (1995) Clinical review 66: Thyroxine suppression therapy for benign nodular diseas. J Clin Endocrinol Metab 80:331–334
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–214
Derwahl M (1995) Spezielle Laboruntersuchungen bei der Diagnose und Therapie von Schilddrüsenkrankheiten. Nuklearmediziner 18:95–103
Derwahl M (1996) Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas. Exp Clin Endocrinol Diabetes 104:32–35
Derwahl M, Studer H (1998) Pathogenesis and treatment of multinodular goiter. In: Fagin J (ed) (1998) Thyroid cancer. Kluwer, Boston Dordrecht London, pp 155–186
Derwahl M, Studer H (2000) Multinodular goitre: “much more to it than simply iodine deficiency”. Baillieres Best Pract Res Clin Endocrinol Metab 14:577–600
Derwahl, M Studer H (2001) Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes 109:250–260
Derwahl M, Studer H (2002) Hyperplasia versus adenoma in endocrine tissues: are they different? Trends Endocrinol Metab 13:23–28
Derwahl M (2011) Linking stem cells to thyroid cancer, J Clin Endocrinol Metab 96:610–613
Doyle P, Düren C, Nerlich K, Verburg FA, Grelle I, Jahn H, Fassnacht M, Mäder U, Reiners C, Luster M (2009) Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 94(8):2970–4
Feldkamp J, Seppel T, Muhlmeyer M, Becker A, Santen R, Schlaghecke R, Horster FA (1996) Therapie der endemischen Sturma mit Jodid oder L-Thyroxin bei älteren Patienten. Med Wochenschr 121:1587–1591
Ferrari C, Reschini E, Paacchi A (1996) Treatment of the autonomous thyroid nodule: a review. Eur J Endocrinol 135:383–390
Frates MC, Benson CB, Doubilet PM, Cibas ES, Marqusee E. Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules? J Ultrasound Med. 2003 Feb;22(2):127–31;
Grussendorf M, Reiners C, Paschke R, Wegscheider K; LISA Investigators (2011) Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 96(9):2786–95
Gharib H, Mazzaferri EL (1998) Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 128:386–394
Gharib H, James EM, Charboneau JW, Naesens JM, Offord KP, Gorman CA (1987) Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 317:70–75
Guglielmi R, Pacella CM, Bianchini A, Bizzarri G, Rinaldi R, Graziano FM, Petrucci L, Toscano V, Palma E, Poggi M, Papini E (2004) Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid 14:125–131
Hedinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumors. In: WHO (ed) International histological classification of tumors, 2nd edn. Springer, Berlin Heidelberg New York Tokyo, pp 5–6
Hintze G Emrich D Köbberling J (1989) Treatment of endemic goitre due to iodine deficiency with iodine, levothyroxine or both: results of a multicentre trial. Eur J Clin Invest 19:527–534
Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M (2009) An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 94(5):1748–51
Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hufner M, Niederle B, Brabant G; German Society for Endocrinology (DGE) – Thyroid Section (2004) Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58
La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A (1995) Levothyroxine and potassium iodide are both effective in treating benign solid cold nodules of the thyroid. Ann Intern Med 122:1–8
La Rosa GL, Ippolito AM, Lupo L, Cercabene G, Santonocito MG, Vigneri R, Belfiore A (1996) Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab 81:4385–4387
Lima N, Knobel M, Cavaliere H, Sztejnsznajd C, Tomimori E, Medeiros-Neto G (1997) Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 7:691–697
Lippi F, Ferrari C, Manetti L et al. (1996) Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter study group. J Clin Endocrinol Metab 81:3261–3264
Livraghi T, Paracchi A, Ferrari C, Bergonzi M, Grarvaglia G, Ranieri P, Vetorri C (1990) Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results. Work in progress. Radiology 175:827–829
Monzani F, Caraccio N, Goletti O et al. (1997) Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Clin Endocrinol (Oxf) 46:9–15
Morita T, Tamai H, Ohshima A, Komaki G, Matsubayashi S, Kuma K, Nakagawa T (1989) Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentration during thyroxine therapy in patients with solitary thyroid nodules. J Clin Endocrinol Metab 69:227–230
Olbricht Th (1995) Schilddrüsensonographie. Nuklearmediziner 18:79–86
Papini E, Bacci V, Panunzi C et al. (1993) A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf) 38:507–513
Papini E, Pacella CM, Verde G (1995) Percutaneous ethanol injection (PEI): what is the role in the treatment of benign thyroid nodules? Thyroid 5:147–150
Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM (2002) Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87:1941–1946
Quadbeck B, Prüllage J, Mann K, Hoermann R (1998) Long-term course of thyroid nodules in euthryoid goiter. Exp Clin Endocrinol Diabetes 106 (suppl 1) (abstract p014)
Reinwein D, Benker G, Windeck R et al. (1989) Erstymptome bei Schilddrüsenmalignomen: Einfluß von Alter und Geschlecht in einem Jodmangelgebiet. Dtsch Med Wochenschr 114:775–782
Spencer CA, Schwarzbein D, Guttler RB, LoPresti JS, Nicoloff JT (1993) Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab 76:494–498
Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia – a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426
Studer H, Ramelli F (1982) Simple goiter and its variants: euthyroid and hyperthyroid multinodular goiter. Endocr Rev 3:40–62
Studer H, Huber G, Derwahl M, Frey P (1989) Die Umwandlung von Basedowstrumen in Knotenkröpfe: ein Grund des Hyperthyreoserezidivs. Schweiz Med Wochenschr 119:203–208
Tonacchera M, Pinchera A, Vitti P (2010) Assessment of nodular goitre. Best Pract Res Clin Endocrinol Metab 24(1):51–61. Review
Trivalle C, Doucet J, Chassagne P, Landrin I, Kadir N, Meard JF, Bercoff E (1996) Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 44:50–53
Verde G, Papini E, Pacell CM et al. (1994) Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin Endocrinol (Oxf) 41:719–724
Wemeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V (2002) Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 87:4928–4934
Bellatone R et al. (2002) Total thyroidectomy for management of benign thyroid disease: review of 526 cases. World J Surg 26:1468–1471
Bellatone R, Lombardi CP, Bossola M et al. (2002) Videoassisted versus conventional thyroid lobectomy. A randomized trial. Arch Surg 137:301–304
Derwahl M (1994) Molekulare Aspekte in der Pathogenese von Knoten und Adenomen der Schilddrüse. Schweiz Med Wochenschr 124:1613–1618
Dralle H, Kruse E, Hamelmann WH et al. (2004) Nicht alle Stimmbandfehlfunktionen nach Schilddrüsenoperationen sind Recurrensparesen infolge intraoperativer Schädigung. Stellungnahme der „Interdisziplinären Studiengruppe Intraoperatives Neuromonitoring Schilddrüsenchirurgie“. Chirurg 75:810–822
Fey MF, Peter HJ, Hinds HL, Zimmermann A, Liechti-Gallati S (1992) Clonal analysis of human tumors with M27b, a highly informative polymorphic x chromosomal probe. J Clin Invest 89:1438–1444
Gemsenjäger E (1983) Anatomie, chirurgische Verfahrenswahl und funktionelle Resultate bei multinodöser Struma. In: Röher HD, Wahl RA (Hrsg) Chirurgische Endokrinologie. Thieme, Stuttgart New York, S 47–57
Gollwitzer M, Matthes P, Nagel B (1987) Über die Rückbildungsfähigkeit der Recurrensparese nach Strumaoperationen. Med Welt 33:172–174
Jatzko GR, Lisborg PH, Müller M, Wette VM (1994) Recurrent nerve palsy after thyroid operations – principal nerve identification and a literature review. Surgery 115:139–144
Joosten U, Brune E, Kersting U, Hohlbach (1997) Risikofaktoren und Verlauf von Recurrensparesen nach Erstoperationen benigner Schilddrüsenerkrankungen. Ergebnisse einer retrospektiven Untersuchung von 1556 Patienten. Zentralbl Chir 122:236–245
Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular pathogenesis of euthoyroid and toxic multinodular goiter. Endocrine Rev 26:504–524
Ladurner D (1990) Das Schilddrüsenszintigramm. Eine Entscheidungshilfe für die Operationstaktik bei Schilddrüsenerkrankungen? Chirurg 61:647–650
Müller C, Dienemann H, Hoffmann et al. (1993) Expandierende Metallmaschenstents zur Behandlung von Trachealstenosen und Tracheomalazie. Zentralbl Chir 118:543–548
Namba H, Matsudo K, Fagin JA (1990) Clonal composition of benign and malignant thyroid tumors J Clin Invest 86:120–125
Nies C, Sitter H, Zielke A et al. (1994) Parathyroid function following ligation of the inferior thyroid artery during bilateral subtotal thyroidectomy. Br J Surg 81:1757–1759
Ortega J, Sala C, Flor B, Iledo S (2004) Efficacy and cost effectiveness of the Ultra Cision Harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. J Laparoendosc Adv Surg Tech 14:9–12
Paschke R (2011) Molecular Pathogenesis of nodular goiter. Langb Arch Surg 396(8):1127–36
Reeve TS, Delbridge L, Cohen A et al. (1987) Total thyroidectomy: the preferred option for multinodular goiter. Ann Surg 206:782–785
Stelzner F (1988) Die chirurgische Anatomie der Grenzlamellen der Schilddrüse und die Nn. laryngei. Langenbecks Arch Chir 373:355–361
Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia – a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426
Thomusch O, Dralle H (2000) Endokrine Chirurgie und evidenzbasierte Medizin. Chirurg 71:635–645
Timmermann W, Hamelmann WH, Thomusch O et al. (2004) Zuverlässigkeit und Konsequenzen des intraoperativen Neuromonitorings in der Schilddrüsenchirurgie. Stellungnahme der „Interdisziplinären Studiengruppe Intraoperatives Neuromonitoring Schilddrüsenchirurgie“. Chirurg 75:916–922
Wheeler MH (1998) Total thyroidectomy for benign thyroid disease. Lancet 351:1526–1527
Zielke A, Clark OH (1995) Benign diseases of the thyroid-parathyroid-adrenal. In: Ritchie WP Jr, Steele GD, Dean RH (eds) General surgery: essentials of practice. Lippincott, Philadelphia
Anderson PE, Hurley PR, Rosswick P (1990) Conservative treatment and long term prophylactic T4 in the prevention of recurence of multinodular goiter. SGO 171:309–313
Bellantone R, Celestino PL, Boschierini M et al. (2004) Predictive factors for recurrence after thyroid lobectomy for unilateral non-toxic goiter in an endemic area: results of a multivariate analysis Surgery 136:1247–51
hjBergfeld G, Risholm L (1963) Postoperative thyroid hormone therapy in non-toxic goiter. Acta Chir Scand 126:531–534
Berglund J, Bondeson L, Christiansen SB et al. (1990) Indications for thyroxine therapy after surgery for non toxic goiter. Eur J Surg 156:433–437
Bistrup C, Nielsen JD, Gregersen G et al. (1994) Preventive effect of levothyroxine in patients operated for non toxic goiter: a randomized trial of one hundred patients with nine year follow up. Clin Endocrinol (Oxf) 40:323–327
Carella C, Mazziotti G, Rotondi M et al. (2002) Iodine improves the effectiveness of thyroxine therapy after surgery for nontoxic goiter: a prospective randomized study. Clin Endocrinol 57:507–513
Feldkamp J, Seppel T, Becker A et al. (1997) Iodide or L-Thyroxine to prevent recurrent goiter in an iodine-deficient area: prospective sonographic study. World J Surg 21:10–14
Geerdsen JP, Frolund L (1986) Thyroid function after surgical treatment of non-toxic goiter. A randomized study of postoperative thyroxine administration. Acta Med Scand 220:341–345
Grussendorf M, Reiners C, Paschke R, Wegscheider K; on behalf of the LISA investigators (2011) Reduction of Thyroid Nodule Volume by Levothyroxine and Iodine Alone and in Combination: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab 96(9)2786–2795
Hedman I, Jansson S, Lindberg S et al. (1986) Need for thyroxine in patients lobectomized for benign thyroid diseases as assessed by follow up on average 15 years after surgery. Eur J Surg 152:481–485
Hegedus L, Hansen JN, Veriergang D et al. (1987) Does prophylactic thyroixine therapy after operation for non toxic goiter influence thyroid size? BMJ 294:801–804
Kann P, Jocham A, Beyer J (1997) Hypothyreose, Hyperthyreose und Therapie mit Schilddrüsenhormonen: Einflüsse auf das Skelettsystem. Dtsch Med Wochenschr 122:1392–1397
Kraimps JL, Marechaud R, Ginseste D et al. (1993) Analysis and prevention of recurrent goiter. SGO 176:319–322
Miccoli P, Antonelli A, Iacconi P et al. (1993) Prospective randomized double blind study about the effectiveness of levothyroxine suppressive therapy in prevention and recurrence after operation: results at the third year of follow up. Surgery 114:1097–1101
Michie W, Pegg CAS, Benscher PD (1972) Prediction of hypothyroidism after partial thyroidectomy for toxic hyperthyroidism. BMJ 1:13–17
Niepomniszcze H, Garcia A, Faure E, Castellanos A, del Carmen Zalazar M, Bur G, Elsner B (2001) Long-term follow-up of contralateral lobe in patients hemithyroidectomized for solitary follicular adenomas. Clin Endocrinol 55:509–513
Peters H, Hackel D, Schleusener H (1996) Rezidivprophylaxe der endemischen Struma. Dtsch Med Wochenschr 121:752–756
Röher HD, Goretzki P (1987) Management of goiter and thyroid nodules in an area of endemic goiter. Surg Clin North Am 67:233–236
Sawin CT, Geller A, Wolf PA et al. (1994) Low serum thyreotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252
Schumm-Draeger PM, Encke A, Usadel KH (2003) Optimal recurrence prevention of iodine deficiency related goiter after thyroid gland operation. A prospective clinical study. Internist 44:420–426; 429–432
Uzzan B, Campos J, Cucherat M et al. (1996) Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278–4289
Bähre M, Hilgers R, Lindemann C, Emrich D (1988) Thyroid autonomy, sensitive detection in vivo and estimation of its functional relavance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 117:145
Baltisberger BL, Minder, CE, Bürgi H (1995) Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol 132:546–549
Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R (1983) Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 56:283
Blum M, Shenkman L, Hollander CS (1975) The autonomous nodule of the thyroid: correlation of patient age, nodule size and functional status. Am J Med Sci 269:43
Coindet JE (1821) Nouvelles recherches sur les effets de l'iode, et sur les précautions a suivre dens le traitement du goitre par ce nouveau remède. Ann Chim Phys (Paris) 16:252
Connolly RJ, Vidor GI, Stewart JC (1970) Increase in thyrotocicosis in endemic goitre after iodination of bread. Lancet 1:500–502
Derwahl M, Manole D, Sobke D, Broecker M (1998) Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Exp Clin Endocrinol Diabetes 106 (suppl 4):6–9
Dremier S, Coppée F, Delange F, Vassart G, Dumont JE, Sande J van (1996) Thyroid autonomy: mechanism and clinical effects. J Clin Endocrinol Metab 81:4187–4193
Emrich D, Bähre M (1978) Autonomy in euthyroid goitre: maladaption to iodine deficiency. Clin Endocrinol (Oxf) 8:257
Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A, Paschke R (2004) Gene expression analsis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules. Oncogene 23:795–804
Hamburger JI (1981) Should all autonomously functioning thyroid nodules be ablated to prevent the subsequent development of thyrotoxicosis? In: Hamburger JI, Miller JM (eds) Controversies in clinical thyroidology. Springer, Berlin Heidelberg New York Tokyo, p 69
Hampel R, Kulberg T, Klein K, Jerichow JU, Pichmann EG, Clausen V, Schmidt I (1995) Goiter incidence in Germany is greater than previously suspected. Med Klin 90:324–329
Joseph K (1992) Funktionelle Autonomie und jodinduzierte Hyperthyreose. Jodmedikation und Hyperthyreose. Akt Endokr Stoffw 13:102
Joseph K (1994) Estimation of the volume of autonomously functioning thyroid tissue. Exp Clin Endocrinol Diabetes 102 (suppl 2):12–19
Joseph K, Mahlstedt J, Gonnermann R, Herbert K, Welcke U (1980a) Early recognition and evaluation of the risk of hyperthyroidism in thyroid autonomy in an endemic goiter area. J Mol Med 4:21
Joseph K, Mahlstedt J, Welcke U (1980b) Autonomously functioning thyroid tissue (AFTT) during iodide prophylaxis. J Mol Med 4:87
Kreisig T, Pickardt CR, Vaitl C, Kirsch CM, Knesewitsch P (1991) Regionaler 99mTc-Uptake der Schilddrüse (TcTU) in Kombination mit Sonographie bei fokaler Autonomie. In: Börner W, Weinheimer B (Hrsg) Schilddrüse 1989. De Gruyter, Berlin, S 208–213
Krohn K, Paschke R (2001) Progression in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab 86:3336–3345
Krohn K, Führer F, Bayer Y, Enzlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular Pathogenesis of Euthyroid and toxic multinodular goiter. Endocrine Reviews 26: 504–24
Laurberg P, Petersen KM, Vestergaard H, Sigurdsson G (1991) High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves‘ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East Jutland, Denmark and Iceland. J Intern Med 229:415–420
Lividas DP, Koutras DA, Souvatzoglu A, Beckers C (1977) The toxic effect of small iodine supplements in patient with autonomous thyroid nodules. Clin Endocrinol (Oxf) 7:121
Mahlstedt J, Joseph K (1973) Dekompensation autonomer Adenome der Schilddrüse nach prolongierter Jodzufuhr. Dtsch Med Wochenschr 98:1748
Miller JM, Horn RC, Block MA (1967) The autonomous functioning thyroid nodule in the evolution of nodular goiter. J Clin Endocrinol Metab 27:1264
Mostbeck A, Galvan G, Bauer P et al. (1998) The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J Nucl Med 25:367–374
Paschke R, Ludgate M (1997) The thyrotropin receptor in thyroid disease. N Engl J Med 337:1675–1681
Pickardt CR (1982) Therapie autonomer Adenome und disseminierter Autonomie. Therapiewoche 32:1015–1018
Plummer HS (1913) The clinical and pathological relationship of simple and exophtalmic goiter. Am J Med Sci 146:790–795
Sandrock D, Olbricht T, Emrich D, Benker G, Reinwein D (1993) Long-term follow-up in patients with autonomous thyroid adenoma. Acta Endocrinol (Copenh) 128:51
Spitzweg C, Joba W, Heufelder AE (1997) Analysis of human sodium iodide symporter gene expression in patients with thyroid diseases. Progr. and Abstr. The Endocrine Society Meeting 1997, Minneapolis, MN, USA p 108
Stanbury JB, Ermans AE, Bourdoux P et al. (1998) Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8:83–100
Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia – a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426
Tonacchera M, Chiovato L, Pinchera A et al. (1998) Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 83:492–498
Vidor GI, Stewart JC, Wall JR, Wangel A, Hetzel BS (1973) Pathogenesis of iodine-induced thyrotoxicosis: studies in nothern Tasmania. J Clin Endocrinol Metab 37:901–909
Blum M, Shenkman L, Hollander CS (1975) The autonomous nodule of the thyroid: correlation of patient age, nodule size and functional status. Am J Med Sci 269:43
Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, Schmidt M (2009) Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun 30: 466–71
De Benoist B,Andersson M, Egli I, Takkouche B, Allen H (editors) (2004) Iodine status worldwide: WHO Global Database on Iodine. WHO, Geneva
Emrich D (1994) Estimation of the autonomous volume. Exp Clin Endocrinol Diabetes 102 (suppl 3):20
Gotthardt M, Stübinger M, Pansegrau J, Buchwald B, Pfestroff A, Goecke J, Corstens FHM, Behr TM (2006) Decrease of 99mTc uptake in autonomous thyroid tissue in Germany since the 1970 s. Clinical implications for radioiodine therapy. Nuklearmedizin 45:122–125
Hillenhinrichs H, Emrich D (1998) Euthyroid goiter with and without functional autonomy in the euthyroid phase: a comparison. Nuklearmedizin 37:95–100
Joseph K, Mahlstedt J, Gonnermann R, Herbert K, Welcke U (1980a) Early recognition and evaluation of the risk of hyperthyroidism in thyroid autonomy in an endemic goiter area. J Mol Med 4:21
Joseph K, Mahlstedt J, Welcke U (1980b) Autonomously functioning thyroid tissue (AFTT) during iodide prophylaxis. J Mol Med 4:87
Joseph K (1994) Estimation of the volume of autonomously functioning thyroid tissue. Exp Clin Endocrinol Diabetes 102 (suppl 2):12–19
Kinser JA, Roesler H, Furrer T, Grütter D, Zimmermann H (1989) Nonimmunogenic hyperthyroidism: cumulative hyperthyroidism incidence after radioiodine and surgical treatment. J Nucl Med 30:1960–1965
Kreisig T, Pickardt CR, Vaitl C, Kirsch CM, Knesewitsch P (1991) Regionaler 99mTc-Uptake der Schilddrüse (TcTU) in Kombination mit Sonographie bei fokaler Autonomie. In: Börner W, Weinheimer B (Hrsg) Schilddrüse 1989. De Gruyter, Berlin, S 208–213
Pfannenstiel P, Hotze LA, Saller B (1997) Schilddrüsenkrankheiten – Diagnose und Therapie. 3. Aufl. BMV, Berlin
Sandrock D, Olbricht T, Emrich D, Benker G, Reinwein D (1993) Long-term follow-up in patients with autonomous thyroid adenoma. Acta Endocrinol (Copenh) 128:51
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation. N Engl J Med 331:1249–1252
Schaller U, Hölzel D, Kirsch C, Engelhardt D (1991) Spontanverlauf von kompensierten autonomen Adenomen. Klein Wochenschr 69:786–792
Zemella V, Leisner B, Calvi J (1989) Spontanverlauf bei der Schilddrüsenautonomie. Der Nuklearmediziner 12:237–249
Becker W, Hohenberger N, Wolf F (1990) Nebenwirkungen und Risiken bei der Radiojodtherapie gutartiger Schilddrüsenerkrankungen. Nuklearmediziner 13:273–280
Bell E, Grünwald F (2000) Radiojodtherapie. Springer, Berlin Heidelberg New York Tokyo
Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, Schmidt M (2009) Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun. 30: 466–71
Bogner L, Czempiel H (1993) Näherungsfehler bei der physikalischen Planung der Radiojodtherapie der Schilddrüse. Nuklearmedizin 32:236–246
Fassbender WJ, Schlutter S, Stracke H, Bretzel RG, Waas W, Tillmans H. Thyroid function after iodine-containing contrast agent administration in coronary angiography: 20 A prospective study of euthyroid patiënts. Z Kardiol 2001; 90: 751 – 9
Fricke E, Fricke H, Esdorn E, Kammeier A, Lindner O, Kleesiek K, Horstkotte D, Burchert W (2004) Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patiënts receiving contrast agent for coronary angiography: A prospective study of patiënts with low thyrotropin. J Clin Endocrinol Metab 89:6092–6
Gotthardt M, Nowack M, Béhé MP, Schipper ML, Schlieck A, Höffken H, Behr TM (2003) Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs-adapted dose concepts the only possible answer? Eur J Nucl Med Mol Imag 30:1165–1168
Gotthardt M, Stübinger M, Pansegrau J, Buchwald B, Goecke J, Pfestroff A, Corstens FH, Behr TM (2006a) Decrease of 99mTc uptake in autonomous thyroid tissue in Germany since the 1970 s. Clinical implications for radioiodine therapy. Nuklearmedizin 45:122–125
Gotthardt M, Rubner C, Bauhofer A, Berce F, Oyen WJG, Goecke J, Pfestroff A, Schlieck A, Corstens FH, Béhé M, Behr TM (2006b) What is the best pretherapeutic dosimetry for successful radioiodine therapy of multifocal autonomy? Nuklearmedizin 45(5):206–12
Huysmans DA, Hermus AR, Corstens FH, Barentz JO, Kloppenburg PWC (1994) Large, compressive goitres treated with rdioiodine. Ann Int Med Clin 121:757–762
Mann K (1998) Evaluation of risk in autonomously funtioning thyroid nodules. Exp Clin Endocrinol Diabetes 106 (suppl 4):23–26
Meller J, Wisheu S, Munzel U, Béhé M, Gratz S, Becker W (2000) Radioiodine therapy for Plummer´s disease based on the thyroid uptake of technetium-99 m-pertechnetate. Eur J Nucl Med 27:1286–1291
Reiners C (1993) Radiojodtherapie – Indikation, Durchführung und Risiken. Dtsch Ärztebl 90:2217–2221
Sandrock D, Olbricht T, Emrich D, Benker G, Reinwein D (1993) Long-term follow-up in patients with autonomous thyroid adenoma. Acta Endocrinol (Copenh) 128:51
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation. N Engl J Med 331:1249–1252
Schaller U, Hölzel D, Kirsch C, Engelhardt D (1991) Spontanverlauf von kompensierten autonomen Adenomen. Klein Wochenschr 69:78792
Schober O, Lerch H (1992) Radiojodtherapie der diffusen Jodmangelstruma. In: Röher HD, Weinheimer B (Hrsg) Schilddrüse 1991. de Gruyter, Berlin New York, S 110–116
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6):593–646
Bay V (1980) Operationsindikation, präoperative Vorbereitung. Operation und Nachbehandlung des Morbus Basedow und anderer Hyperthyreoseformen. Chirurg 51:619–624
Burch HB, Wartofsky L (1993) Life-threatening thyreotoxicosis. Thyroid storm. Endocrinol Metab North Am 22:263–268
Brooks MH, Waldstein SS (1980) Free thyroxine concentrations in thyroid storm. Ann Intern Med 93:694–697
Chong HW, See KC, Phua J (2010) Thyroid storm with multiorgan failure. Thyroid 20(3):333–6
Dralle H, Schneyer U, Scharbert G (1998) Chirurgie der jodinduzierten Hyperthyreose. In: Reiners C, Weinheimer B (Hrsg.) Schilddrüse. de Gruyter, Berlin, S 310–318
Frilling A, Goretzki P, Horster A, Gussendorf M, Röher HD (1990) Subtotale Thyroidektomie als Therapiekonzept der thyreotoxischen Krise. Dtsch Med Wochenschr 115:735–739
Hamburger JI (1980) Evolution of toxicity in solitary nontoxic functioning thyroid nodules. J Clin Endocrinol Metab 50:1089–1093
Hehrmann R (1996) Die thyreotoxische Krise: Fallstricke in der Diagnostik-Intensivtherapie. Fortschr Med 114:26–31
Hintze G (1992) Thyreotoxische Krise: Stellenwert der chirurgischen Therapie. Akt Endokr Stoffw 13:89–91
Karger S, Führer D (2008) Thyreotoxische Krise – ein Update. Dtsch Med Wochenschr 133(10):479–84. Review
Koball S, Hickstein H, Gloger M, Hinz M, Henschel J, Stange J, Mitzner S (2010) Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: a case report. Artif Organs 34(2):E55–8
Kocher T (1874) Ueber Kropf Extirpation und ihre Folgen. Arch Klin Chir (Berlin) 29:539
Kokott P. (2009) Thyreotoxische Krise. MMW Fortschr Med. 151(19):40
Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular pathogenesis of euthoyroid and toxic multinodular goiter Endocrine Rev 26:504–524
Lederbogen S, Reinwein D (1992) Epidemiologische Daten zur thyreotoxischen Krise. Akt Endokr Stoffw 13:82–84
Meurisse M, Gollogly L, Degauque C, Fumal I, Defechereux T, Hamoir E (2000) Iatrogenic thyreotoxicosis: causal circumstances, pathophysiology and principles of treatment:review of the literature. World J Surg 24:1377–1385
Mikulicz (1886) Beitrag zur Operation des Kropfes. WMW 36:1–6; 40–44, 70–74, 97–101
Müller-Gärtner HW, Scheider C, Riechert B, Kayser D, Kremer B (1989) Langzeitergebnisse nach Operation oder Radiojodtherapie des solitären autonomen Adenoms der Schilddrüse. Chirurg 60:33–35
Muller AF, Berghout A, Wiersinga WM, Kooy A, Smits JW, Hermus AR; working group Thyroid Function Disorders of the Netherlands Association of Thyroid function disorders (2008) Guidelines of the Netherlands Association of Internal Medicine. Internal Medicine. Neth J Med. 66(3):134–42
Namba H, Matsudo K, Fagin JA (1990) Clonal composition of benign and malignant thyroid tumors. J Clin Invest 86:120–125
Paschke R, Hegedüs L, Alexander E, Valcavi R, Papini E, Gharib H (2011) Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol 7: 354–361
Plummer HS, Boothby WM (1923) Value of iodin in exophtalmic goiter. Collected papers Mayo Clin 15:565–567
Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML (2008) Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J Surg 32(7):1278–84
Reichmann I, Frilling A, Hormann R, Krause U, Broelsch CE (2001) Frühoperation als Behandlungsmassnahme der thyreotoxischen Krise. Chirurg 72:402–407
Reinwein D, Benker G, Alexander WD, Lazarus JH (1993) and the european multicenter study group of antithyroid drugs in the management of Graves‘ hyperthyroidism. J Clin Endocrinol Metab 76:1516–1522
Röher HD, Goretzki P (1987) Management of goiter and thyroid nodules in an area of endemic goiter. Surg Clin North Am 67:233–236
Röher HD, Hiorster FA, Frilling A, Goretzki P (1991) Morphologie und funktionsgerechte Chirurgie verschiedener Hyperthyreoseformen. Chirurg 62:176–181
Scholz GH, Hageman E, Arkenau C et al. (2003) Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? Thyroid 13:933–940
Stålberg P, Svensson A, Hessman O, Akerström G, Hellman P. (2008) Surgical treatment of Graves' disease: evidence-based approach. World J Surg 32(7):1269–77
Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia – a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426
Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ito K (2008) Surgical management of Graves' disease -10-year prospective trial at a single institution. Endocr J 55(1):161–7
Trivalle C, Doucet J, Chassagne P et al. (1996) Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 44:50–53
Weber C, Scholz GH, Lamesch P, Paschke R (1999) Thyroidectomy in iodine induced thyrotoxic storm. Exp Clin Endocrinol Diabetes 107:468–472
Bay V (1980) Operationsindikation, präoperative Vorbereitung, Operation und Nachbehandlung des Morbus Basedow und anderer Hyperthyreoseformen. Chirurg 51:619–624
Dorbach M, Schicha H (1993) Frequenz und zeitliches Auftreten der funktionellen Autonomie in Rezidivstrumen. Nuklearmedizin 32:316–319
Emrich D, Reinhardt M (1989) Ergebnisse der definitiven Behandlung der Autonomie bei Jodmangelstruma. Nuklearmedizin 28:11–17
Joseph K (1986) Thyreoidale Autonomie: Diagnostik, Therapie und Nachsorge. Therapiewoche 36:1711–1716
Röher HD, Goretzki P (1987) Management of goiter and thyroid nodules in an area of endemic goiter. Surg Clin North Am 67:233–236
Röher HD, Horster FA, Frilling A, Goretzki P (1991) Morphologie und funktionsgerechte Chirurgie verschiedener Hyperthyreoseformen. Chirurg 62:176–181
Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ito K (2008) Surgical management of Graves' disease -10-year prospective trial at a single institution. Endocr J 55(1):161–7
Wahl RA, Joseph K, Bögner E et al. (1985) Thyroid function after surgery for autonomous nodular endemic goitre-effect of iodide-substitution. Klin Wochenschr 63:812–820
Andermann P, Schlögl S, Mäder U, Luster M, Lassmann M, Reiners C (2007) Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin 46:1–7
Eckstein A, Mann K, Kahaly GJ, Grussendorf M, Reiners C, Feldkamp J, Quadbeck B, Bockisch A, Schott M (2009) Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology. Med Klin 15:343–348
Eckstein A, Esser J, Mann K, Schott M (2010) Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. Pediatr Endocrinol 7 Suppl 2:198–203
Gharib H, Papini E, Paschke R, et al.; (2010) AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract 16 Suppl 1:1–43
Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 34:307–313
Michalek K, Morshed SA, Latif R, Davies TF (2009) TSH receptor autoantibodies. Autoimmun Rev 9:113–116
Mizokami T, Wu Li A, El-Kaissi S, Wall JR (2004) Stress and thyroid autoimmunity. Thyroid 14:1047–1055
Quadbeck B, Roggenbuck U, Janssen OE, Hahn S, Mann K, Hoermann R, Basedow Study Group (2006) Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs. Exp Clin Endocrinol Diabetes 114:406–411
Putta-Manohar S, Perros P (2010) Epidemiology of Graves' orbitopathy. Pediatr Endocrinol Rev 7 Suppl 2: 182–185
Rivkees SA (2006) The treatment of Graves' disease in childre. J Pediatr Endocrinol Metab 19:1095–1111
Stan MN, Bahn RS (2010) Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 20:777–783
Tomer Y (2010) Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid. 20: 715–725
Weetman AP (2000) Graves' disease. N Engl J Med 343:1236–1248
Weetman AP (2011) Autoimmune thyroid disease. In: Wass JAH, Stewart PM (eds) Oxford Textbook of Endocrinology and Diabetes, London, pp 416–431
Zöphel K, Roggenbuck D, Wunderlich G, Schott M (2010) Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays. Horm Metab Res 42:900–902
Zöphel K, Roggenbuck D, Schott M (2010) Clinical review about TRAb assay's history. Autoimmun Rev 9:695–700
Allanic H, Fauchet R, Orgiazzi J et al. (1990) Antithyroid drugs and Graves‘ disease: A prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70:675–679
Balazs C, Stenszky V, Farid NR (1999) Association between Graves´ ophthalmopathy and smoking. Lancet 22:336–354
Cooper DS (1998) Antithyroid drugs for the treatment of hyperthyroidism caused by Graves‘ disease. Endocrinol Metab Clin North Am 27:225–247
Costagliola S, Morgenthaler NG, Hoermann R (1999) Second generation assay for TSH-receptor antibodies has superior diagnostic sensitivity in Graves´disease. J Clin Endocrinol Metab 84:90–97
Edmonds CJ, Tellez M (1994) Treatment of Graves‘ disease by carbimazole: High dose with thyroxine compared to titration dose. Eur J Endocrinol 131:120–124
Feldt-Rasmussen U, Schleusener H, Carayon P (1994) Meta-analysis: Evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves‘ disease. J Clin Endocrinol Metab 78:98–102
Glaser NS, Styne DM (1997) Predictors of early remission of hyperthyroidism in children. JCEM 82:1719–1726
Glinoer D, de Nayer P, Bex M, Belgian Collaboration Study Group on Graves´disease (2002) Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves´hyperthyroidism treated with antithyroid drugs: a double blind prospective randomized study. Eur J Endocrinol 144:475–483
Hashizume K, Ichikawa K, Sakurai A et al. (1991) Administration of thyroxine in treated Graves‘ disease. Effects on the level of antibodies to thyroid-stimulating receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324:947–953
Hoermann R, Quadbeck B, Roggenbruck U, Basedow Study Group (2002) Relapse of Graves´disease after successful outcome of antithyroid drug therapy: Results of a prospective randomized study on the use of levothyroxine. Thyroid 12:1119–1128
Mann K, Dralle H, Gärtner R et al. (1997) Schilddrüse. In: Rationelle Therapie in der Endokrinologie. Thieme, Stuttgart New York, S 35–98
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A (1996) Lack of effect of thyroxine patients with Graves‘ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 334:220–224
Meng W, Meng S, Männchen E, Hampel R, Kirsch, Dannenberg GJ, Krabbe S (1991) Effect of therapy duration and low and highly dosed thiamazole treatment in Basedow-Graves‘ disease. Exp Clin Endocrinol Diabetes 97:257–260
Quadbeck B, Hoermann R, Janssen O E, Mann K (2003) Medikamentöse Behandlung der Immunhyperthyreose (Typ Morbus Basedow). Internist 44:440–448
Reinwein D, Benker G, Alexander WD, Lazarus JH and the European multicenter study group of antithyroid drug treatment (1993) A prospective randomized trial of antithyroid drug dose in Graves‘ disease therapy. J Clin Endocrinol Metab 76:1516–1521
Rittmaster RS, Abbott EC, Douglas R et al. (1998) Effect of methimazole, with or without L-Thyroxine, on remission rates in Graves‘ disease. JCEM 83:814–818
Schleusener H, Schwander J, Fischer C et al. (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves‘ disease. Acta Endocrinol 120:689–701
Schumm-Draeger P-M, Müller O-A (2003) Therapie der Hyperthyreose. Dtsch Med Wschr 128:500–502
Wilson JD, Forster DW (1998) William's textbook of endocrinology, 9th ed. Saunders, Philadelphia
Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U (2002) Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves´disease. Eur J Endocrinol 146:173–177
Allahabadia A, Daykin J, Holder RL et al. (2000) Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 85:1038–1042
Bartalena L, Marcocci C, Fausto B et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves‘ ophthalmopathy. N Engl J Med 338:73–78
Dederichs B, Otte R, Klink JE, Schicha H (1996) Volumenreduktion der Schilddrüse nach Radiojodtherapie bei Patienten mit Schilddrüsenautonomie und Morbus Basedow. Nuklearmedizin 35:164–169
Dederichs B, Dietlein M, Jenniches-Kloth B et al. (2006) Radioiodine therapy of Graves’ hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? Exp Clin Endocrinol Diabetes 114:366–370
Dietlein M, Dressler J, Grünwald F et al. (2003) Leitlinien zur Schilddrüsendiagnostik (Version 2). Nuklearmedizin 42:109–115
Dietlein M, Dressler J, Eschner W et al. (2007a) Verfahrensanweisung zum Radioiodtest (Version 3). Nuklearmedizin 46: 198–202
Dietlein M, Dressler J, Grünwald F et al. (2007b) Leitlinie zur Radioiodtherapie bei benignen Schilddrüsenerkrankungen (Version 4). Nuklearmedizin 46:220–223
Dunkelmann S, Wolf R, Koch A et al. (2004) Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 31:1428–1434
Franklyn JA, Maisonneuve P, Sheppard M et al. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353:2111–2115
Kobe C, Eschner W, Sudbrock F et al. (2008) Graves’ disease and radioiodine therapy: is success of ablation dependent on the absorbed dose above 200 Gy? Nuklearmedizin 47:13–17
Kobe C, Weber I, Eschner W et al. (2008) Graves’ disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication? Nuklearmedizin 47:153–166
Kobe C, Eschner W, Wild M et al. (2010) Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun 31:201–205
Michelangeli V, Poon C, Taft J et al. (1998) The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid 8:119–124
Nieuwlaat WA, Hermus AR, Sivro-Prndelj F et al. (2001) Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 86:5330–-5336
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H (1995) Radioiodine therapy of Graves‘ hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized multicentre study. Eur J Clin Invest 25:186–193
Reiners Chr (1993) Radiojodtherapie. Dtsch Ärzteblatt 90:B-2217–2221
Richtlinie Strahlenschutz in der Medizin 2011. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung – StrlSchV). Veröffentlicht am 30.11.2011 im Gemeinsamen Ministerialblatt S. 867 [www.bmu.de/strahlenschutz]
Ron E, Doody MM, Becker DV et al. (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280:347–355
Schicha H, Scheidhauer K (1993) Radiojodtherapie in Europa – eine Umfrage. Nuklearmedizin 32:321–324
Schicha H (1997) Muss die hohe Hypothyreoserate nach Radiojodtherapie einer immunogenen Hyperthyreose in Kauf genommen werden? Nuklearmedizin 36:6
Schicha H, Dietlein M (2002) Morbus Basedow und Autonomie – Radioiodtherapie. Nuklearmedizin 41:63–70
Schicha H, Dietlein M, Scheidhauer K (1999) Therapie mit offenen radioaktiven Stoffen. In: Büll U, Schicha H, Biersack HJ, Knapp WH, Reiners Chr, Schober O (Hrsg) Nuklearmedizin, 3. Aufl. Thieme, Stuttgart New York, S 512–545
Schicha H, Reiners C, Moser E, Schober O (2004) Subclinical thyroid disease. Nuklearmedizin 43:69–104
Silva MNC, Rubio IGS, Romao R et al. (2004) Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol 60:300–308
Strahlenschutzkommission „Ambulante, fraktionierte Radioiodtherapie“, Empfehlung der Strahlenschutzkommission vom 22./23. Februar 1996. Bundesanzeiger Nr. 132 (18.7.1996)
Strahlenschutzkommission „Strahlenschutzgrundsätze für die Radioiodtherapie“, Empfehlung der Strahlenschutzkommission vom 5./6. Dezember 1996. Bundesanzeiger Nr. 68 (11.4.1997)
Strahlenschutzverordnung (StrlSchV) (2011) Verordnung über den Schutz vor Schäden durch ionisierende Strahlen vom 20. Juli 2001 (BGBL. I S. 1714), die zuletzt durch Artikel 1 der Verordnung vom 4. Oktober 2011 (BGBl. I S. 2000) geändert worden ist [www.juris.de]
Vitti P, Rago T, Chiovato L (1997) Clinical features of patients with Graves‘ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375
Wesche MF, Tiel-Van Buul MM, Lips P, Smits NJ, Wiersinga WM (2001) A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 86:998–1005
Weigand A, Hinzpeter B, Schicha H (1998) Verschlechterung einer endokrinen Orbitopathie nach Radioiodtherapie bei M. Basedow? Nuklearmedizin 37:234–238
Acharya SH, Avenell A, Philip S et al. (2008) Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 69:943–950
Anonymous (1998) Leitlinie zur Therapie der benignen Struma. In: Mitteilungen der Dt. Ges. f. Chirurgie. Stuttgart
Bahn Chair RS, Burch HB, Cooper DS et al. (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646
Barakate MS, Agarwal G, Reeve TS et al. (2002) Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg 72:321–324
Biet A, Zaatar R, Strunski V et al. (2009) [Postoperative complications in total thyroidectomy for Graves disease: comparison with multinodular benign goiter surgery]. Ann Otolaryngol Chir Cervicofac 126:190–195
Boostrom S, Richards ML (2007) Total thyroidectomy is the preferred treatment for patients with Graves' disease and a thyroid nodule. Otolaryngol Head Neck Surg 136:278–281
Cappelli C, Braga M, De Martino E et al. (2006) Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: experience at an endocrine center in Italy. Surg Today 36:125–130
Cardis E, Kesminiene A, Ivanov V et al. (2005) Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97:724–732
Chung JO, Cho DH, Chung DJ et al. (2010) Ultrasonographic features of papillary thyroid carcinoma in patients with Graves' disease. Korean J Intern Med 25:71–76
Cooper DS (2003) Hyperthyroidism. Lancet 362:459–468
Digonnet A, Willemse E, Dekeyser C et al. (2010) Near total thyroidectomy is an optimal treatment for graves' disease. Eur Arch Otorhinolaryngol 267:955–960
Dralle H (1999) Current status of total thyroidectomy in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107 Suppl 5:S195–197
Dralle H, Sekulla C (2004) [Morbidity after subtotal and total thyroidectomy in patients with Graves' disease: the basis for decision-making regarding surgical indication and extent of resection]. Z Arztl Fortbild Qualitatssich 98 Suppl 5:45–53
Erbil Y, Barbaros U, Ozbey N et al. (2008) Graves' disease, with and without nodules, and the risk of thyroid carcinoma. J Laryngol Otol 122:291–295
Erbil Y, Ozluk Y, Giris M et al. (2007) Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 92:2182–2189
Feliciano DV, Lyons JD (2011) Thyroidectomy is optimal treatment for Graves' disease. J Am Coll Surg 212:714–720; discussion 720–711
Gerenova J, Buysschaert M, De Burbure CY et al. (2003) Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med 14:321–325
Kasuga Y, Sugenoya A, Kobayashi S et al. (1993) The outcome of patients with thyroid carcinoma and Graves' disease. Surg Today 23:9–12
Kinkel B, Bucerius J, Risse JH (2007) [Graves' disease and papillary thyroid cancer--coincidence or association?]. Dtsch Med Wochenschr 132:983–986
Koyuncu A, Aydin C, Topcu O et al. (2010) Could total thyroidectomy become the standard treatment for Graves' disease? Surg Today 40:22–25
Ku CF, Lo CY, Chan WF et al. (2005) Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves' disease. ANZ J Surg 75:528–531
Laurberg P, Bournaud C, Karmisholt J et al. (2009) Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 160:1–8
Lepner U, Seire I, Palmiste V et al. (2008) Surgical treatment of Graves' disease: subtotal thyroidectomy might still be the preferred option. Medicina (Kaunas) 44:22–26
Liu J, Bargren A, Schaefer S et al. (2011) Total Thyroidectomy: A Safe and Effective Treatment for Graves' Disease. J Surg Res
Musholt TJ, Clerici T, Dralle H et al. (2011) German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 396:639–649
Palit TK, Miller CC, 3rd, Miltenburg DM (2000) The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res 90:161–165
Patil-Sisodia K, Mestman JH (2010) Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 16:118–129
Pesce CE, Shiue Z, Tsai HL et al. (2010) Postoperative hypocalcemia after thyroidectomy for Graves' disease. Thyroid 20:1279–1283
Phitayakorn R, Mchenry CR (2008) Incidental thyroid carcinoma in patients with Graves' disease. Am J Surg 195:292–297; discussion 297
Rivkees SA (2006) The treatment of Graves' disease in children. J Pediatr Endocrinol Metab 19:1095–1111
Rivkees SA, Dinauer C (2007) An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 92:797–800
Robert J, Mariethoz S, Pache JC et al. (2001) Short- and long-term results of total vs subtotal thyroidectomies in the surgical treatment of Graves' disease. Swiss Surg 7:20–24
Rotondi M, Cappelli C, Pirali B et al. (2008) The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93:3985–3988
Rubio Cabezas O, Munoz Calvo MT, Pozo Roman J et al. (2004) [Graves' disease in children: management and review of 20 patients]. An Pediatr (Barc) 61:131–136
Stalberg P, Svensson A, Hessman O et al. (2008) Surgical treatment of Graves' disease: evidence-based approach. World J Surg 32:1269–1277
Sugino K, Ito K, Nagahama M et al. (2008) Surgical management of Graves' disease -10-year prospective trial at a single institution. Endocr J 55:161–167
Wilhelm SM, Mchenry CR (2010) Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves' disease in the United States. World J Surg 34:1261–1264
Yabuta T, Ito Y, Hirokawa M et al. (2009) Preoperative administration of excess iodide increases thyroid volume of patients with Graves' disease. Endocr J 56:371–375
Yano Y, Shibuya H, Kitagawa W et al. (2007) Recent outcome of Graves' disease patients with papillary thyroid cancer. Eur J Endocrinol 157:325–329
Adams PC, Holt DW, Storey GC et al. (1985) Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 72:1064–1075
Bähre M, Hilgers R, Lindemann C et al. (1987) Physiological aspects of the thyroid trapping function and its suppression in iodine deficiency using 99mTc pertechnetate. Acta Endocrinol 115:175–182
Bogazzi F,Bartalena L,Martino E (2010) Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab 95:2529–2535
Bogazzi F, Martino E, Dell’Unto E et al. (2003) Thyroid color flow Doppler sonography and radioiodine uptake in consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 26:635–640
Broussolle C, Ducottet X, Martin C et al. (1989) Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. J Endocrinol Invest 12:37–42
Fricke E, Fricke H, Esdorn E, et al. (2004) Szintigraphy for Risk Stratification of Iodine-Induced Thyrotoxicosis in Patients Recieving Contrasast Agent for Coronary Angiography:A Prospective Study of Patients with Low Thyrotropin. J Clin Endocrinol Metab 89(12):6092–6096
Gärtner R (1989) Wirkungen von Amiodaron auf die Schilddrüsenfunktion. Med Klin 84:396–399
Gotthardt M,Stübinger M,Pansegrau J, et al. ( 2006) Abfall des 99Tc-Uptakes in autonomen Schilddrüsengewebe in Deutschland seit den 1970er Jahren:Implikationen für die Radiojodtherapie. Nuklearmedizin 45(3):122–125
Kishore J, Licata A (1998) Effects of amiodarone on thyroid function. Ann Intern Med 126:63–73
Köbberling J, Hintze G, Becker HD (1985) Iodine-induced thyrotoxicosis – a case for subtotal thyroidectomy in severeley ill patients. Klin Wochenschr 63:1–7
Le Heuzey J Y,De Ferrari G M, Radzik D et al. (2010) A short-term, randomized,double-blind,parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation:the DIONYSOS study
Nolte W, Müller R, Siggelkow H et al. (1996) Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. Eur J Endocrinol 134:337–341
Pitsiavas V, Smerdely P, Li M, Boyages StC (1997) Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine excess alone in the BB/W rat and the Wistar rat. Eur J Endocrinol 137:89–98
Reinwein D, Benker G, König MP (1987) Klinische Aspekte der Hyperthyreose in Gebieten unterschiedlicher Jodversorgung. Schweiz Med Wochenschr 117:1245–1255
Taurog A (1976) The mechanism of action of the thioureylene antithyroid drugs. Endocrinology 98(4):1031–46
AACE/AME/ETA (2010) Thyroid Nodule guidelines. Endocr Pract 16(Suppl 1)
Baloch ZW, LiVosli VA, Asa Sl et al. (2008) Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyoid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol 36:425–437
Barroeta JE, Wang H, Shiina N, Gupta PK, Livolsi VA, Baloch ZW (2006) Is fine-needle aspiration (FNA) of multiple thyroid nodules justified? Endocr Pathol 17(1):61–65
Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O, Vigneri R (1987) The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer 15(60):3096–3102
Brauer VFH, Hentschel B, Paschke R (2003) Der euthyreote Schilddrüsenknoten. DMW 128:2381–2387
Brooks JR, Starnes HF, Brooks CD, Pelkey JN (1988) Surgical therapy for thyroid carcinoma. A review of 1249 solitary thyroid nodules. Surgery 104:940–946
Castro MR, Caraballo PJ, Morris JC (2002) Effectiveness of thyroid homone suppressive therapy in benign solitary thyroid nodules: a meta analysis. J Clin Endocrinol Metab 87:4154–4159
Corrias A, Einaudi S, Chiorboli E et al. (2001) Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: Comparism with conventional clinical, laboratory and imaging approaches. J Clin Endocrinol Metab 86:4644–4648
Dietlein M, Dressler J, Joseph K et al. (1999) Guidelines in a thyroid diagnosis. Nuklearmedizin 38:215–218
Frates MC, Benson CB, Doubilet PM et al. (2006) Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endorcinol Metab 91:3411–3417
Führer D, Holzapfel HP, Ruschenberg I, Paschke R (2001) Diagnostik des Schilddrüsenknotens. Dtsch Arzteblatt 38:2427–2437
Gharib H, Papini E, Paschke R et al. (2010) American Association of Clinical Endocrinologists, Italian Association of Clinical Endocrinologists and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 16 (Suppl 2):1–20
Gussendorf M, Vaupel R, Reiners C, Wegschneider K (2005) Die LISA-Studie – eine randomisierte, doppelblinde, vierarmige, plazebokontrollierte, multizentrische Studie an 1000 Patienten über die medikamentöse Therapie der Struma in Deutschland. Med Klinik 100:542–546
Hagag P, Strauss S, Weiss M (1998) Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyorid nodules. Thyroid 8: 989–995
Hegedus L (2001) Thyroid ultrasound. Endocrinol Metab Clin North Am 30:339–360
Horvath E, Majlis S, Rossi R et al. (2009) An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 94:1748–1751
Loh KC (1997) Familiar nonmedullary thyroid carcinoma: A metre-review of case series. Thyroid 7:107–113
Mandel SJ (2004) Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract 10:246–252
McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE,Yim JH (2008) The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 142(6):837–844. Discussion 844 e1–3
Papini E, Guglielmi R, Bianchini A et al. (2002) Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87:1941–1946
Paschke R, Reiners C, Führer D, Schmid KW, Dralle H Brabant G (2005) Empfehlungen und offenen Fragen inder Diagnostik und Therapie von Schilddrüsenknoten. DMW 130:1831–1836
Pfannenstiel P (1988) Sonographie und gezielte Feinnadelpunktion der Schilddrüse. Internist 29:545–549
Pfannenstiel P (1989) Wertigkeit der Sonographie bei der Diagnostik bei Schilddrüsenknoten. In: Röher HD, Rothmund M (Hrsg) Endokrine Chirurgie. Urban & Schwarzenberg, München
Punales MK, da Rocha AP, Meotti C, Gross JL, Maia AL (2008) Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2 A. Thyroid 18:1261–1268
Raza SN, Shah MD, Palme CE, Hall FT, Eski S, Freeman JL (2008) Risk factors for well-differentiated thyroid carcinoma in patients with thyroid nodular desease. Otolaryngol Head Neck Surg 139(1):21–26
Reinwein D, Benker G, Windeck R et al. (1989) Erstbefunde beim Schilddrüsenkarzinom. Einfluss von Alter und Geschlecht in einem Jodmangelgebiet. Dtsch Med Wochenschr 114:775–779
Richter B, Neuises G, Clar C (2002) Pharmacotherapy for thyroid nodules. A systematic review and meta-analysis. Endocrinol Metab Clin North Am 31:699–722
Röher, HD, Goretzki P (1986) Der „kalte“ Schilddrüsenknoten. Langenbecks Arch Chir 369:191–194
Rosai J, Carcangiu ML, DeLellis RA (1992) Tumors of the thyroid gland. Washington DC: Armed Forces Institute of Pathology
Rosenbaum MA, McHenry CR (2009) Contemporary management of papillary carcinoma of the thyroid gland, Expert Rev Anticancer Ther 9:317–329
Ross DS (2012) Diagnostic approach to an treatment of thyroid nodules. In: Rose BD (ed) UpToDate. Wellesley, MA: UpToDate. Last accessed April 2012
Rothmund M, Zielke A (1991) Der solitäre Schilddrüsenknoten – befundgerechte Operation. Chirurg 62:162–168
Slowinska-Klencka D, Klencki M, Sporny S, Lewinski A (2002) Fine-needle aspiration biopsy of the thyroid in an area of endemic goitre: Influence of restored sufficient iodine supplementation on the clinical significance of cytological results. Eur J Endocrinol 146:19–26
Volzke H, Ludemann J, Robinson DM et al. (2003) The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 13:803–810
Zedenius J, Auer G, Bäckdahl C et al. (1992) Follicular tumors of the thyroid gland: diagnosis, clinical aspects and nuclear DNA analysis. World J Surg 16:589–594
Zielke A, Clark OH (1995) Benign diseases of the thyroid-parathyroid-adrenal. In: Ritchie WP Jr, Steele GD, Dean RH (eds) General surgery: essentials of practice. Lippincott, Philadelphia
Hegazy MA, Khater AA et al. (2007) Minimally invasive video-assisted thyroidectomy for small follicular thyroid nodules. World J Surg 31:1743–50
Henry JF et al. (2008) Minimally invasive thyroid and parathyroid surgery is not a question of length of the incision. Langenbecks Arch Surg 393:621–26
Ikeda Y et al. (2000) Endoscopic neck surgery by the axillary approach. J Am Coll Surg 191:336
Lombardi CP, Raffaelli M et al. (2005) Safety of video-assisted thyroidectomy versus conventional surgery. Head Neck 27:58–64
Miccoli P, Berti P, Bendinelli C, Marcocci C (1999) Minimally invasive surgery for thyroid small nodules: preliminary report. J Endocrinol Invest 22:849–51
Miccoli P, Berti P et al. (2001) Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: a prospective randomized study. Surgery 130:1039–43
Miccoli P, Bellantone R et al. (2002) Minimally invasive video-assisted thyroidectomy: multiinstitutional experience. World J Surg 26:972–5
Miccoli P et al. (2002) Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of ist completeness. Surgery 132:1070–3
Ohgami M, Ishii S et al. (2000) Scarless endoscopic thyroidectomy: breast approach for better cosmesisi. Surg Laparosc Endosc Percutan Tech 10:1–4
Park CS et al. (2001) Minimally invasive open thyroid surgery Surgery Today 31:665–69
Radford PD, Ferguson MS et al. (2011) Metaanalysis of minimally invasive video-assisted thyroidectomy. Laryngoscope 121:1675–81
Schabram J et al. (2004) Differentiated operative strategy in minimally invasive, video-assisted thyroid surgery results in 196 patients. World J Surg 28:1282–6
Schardey HM, Schopf C et al. (2008) Invisible scar endoscopic thyroidectomy by the dorsal approach: experimental development of a new technique with human cadavers and preliminary clinical results. Surg Endosc 22:813–20
Witzel K et al. (2008) Transoral access for endoscopic thyroid resection. Surg Endosc 22:1871–5
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Arora N, Scognamiglio T, Zhu B, Fahey TJ 3rd (2008) Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg 32:1237–1246
Bongarzone I, Butti MG, Fugazzola L, et al. (1997) Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics 42:252–259
Bülow C, Bülow S (1997) Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 12:240–242
Carcangiu ML, Zampi G, Rosai J (1984) Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am J Surg Pathol 8:655–668
Cavaco BM, Batista PF, Martins C, et al. (2008) Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer 15:207–215
Chan JK, Rosai J (1991) Tumors of the neck showing thymic or related branchial pouch differentiation: a unifying concept. Hum Pathol 22:349–367
Charkes ND (2006) On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid 16: 181–186
Cheung L, Messina M, Gill A, et al. (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–357
Clerici T, Kolb W, Beutner U, et al. (2010) Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg 97:839–844
Collini P, Sampietro G, Pilotti S (2004) Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hürthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology 44:35-39
Elisei R, Cosci B, Romei C, et al. (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687
Franc B, de la Salmonière P, Lange F, et al. (2003) Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34:1092–1100
Führer D, Schmid KW (2010) Benigner oder maligner Schilddrüsenknoten? Internist 51:611–619
Harach HR, Franssila KO, Wasenius VM (1985) Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56: 531–538
Harach HR, Wilander E, Grimelius L, et al. (1992) Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma. Pathol Res Pract 188:123–130
Harach HR (1997) Histogenesis of thyroid C-cell carcinoma. Curr Top Pathol 91:15–20
Harb WJ, Sturgis EM (2009) Differentiated thyroid cancer associated with intestinal polyposis syndromes: a review. Head Neck 31:1511–1519
He H, Jazdzewski K, Li W, Liyanarachchi S, et al. (2005) The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 102: 19075– 19080
Hermann M, Tonninger K, Kober F, Furtlehner EM, Schultheis A, Neuhold N (2010) Minimally invasive follicular thyroid carcinoma: Not always total thyroidectomy. Chirurg 81:627–30
Hofman V, Lassalle S, Bonnetaud C, et al. (2009) Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 455:21–33
Jochum W, Padberg BC, Schröder S (1994) Lymphoepitheliales Karzinom der Schilddrüse. Pathologe 15: 361–365
Karger S, Weidinger C, Krause K, et al. (2009) FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 16:189–199
Koperek O, Scheuba C, Cherenko M, et al. (2008) Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathology 52:623–630
Liaw D, Marsh DJ, Li J, Dahia PL, et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64–67
Machens A, Holzhausen HJ, Dralle H (2005) The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103:2269–2273
Mulligan LM, Eng C, Healey CS, et al. (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2 A and FMTC. Nat Genet 6: 70–74
Musholt PB, Musholt TJ, Morgenstern SC, et al. (2008) Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg 32:722–728
Musholt TJ, Musholt PB, Petrich T, et al. (2000) Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 24:1409–1417
Nikiforova MN, Lynch RA, Biddinger PW, et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–2326
Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8:83–95
Pilarsky R (2009) Cowden Syndrome: a critical review of the clinical literature. J Gent Counsel 18:13–27
Roka S, Kornek G, Schuller J, et al. (2004) Carcinoma showing thymic-like elements – a rare malignancy of the thyroid gland. Br J Surg 91:142–145
Rosai J, Carcangiu M, DeLellis RA (1992) Tumors of the thyroid gland. In: Atlas of Tumor Pathology, Vol 5. AFIP, Washington/DC
Rosai J (2005) Handling of thyroid follicular patterned lesions. Endocr Pathol 16:279–283
Saggiorato E, Rapa I, Garino F, et al. (2007) Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia. J Mol Diagn 9:214–219
Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855
Schmid KW, Tötsch M, Öfner D, Böcker W, Ladurner D (1997) Minimally invasive follicular thyroid carcinoma: a clinico-pathological study. Curr Top Pathol 91:37–43
Schmid KW, Ensinger C (1998) "Atypical" medullary thyroid carcinoma with little or no calcitonin expression. Virchows Arch 433: 209–215
Schmid KW, Sheu SY, Görges R, Ensinger C, Tötsch M (2003) Tumoren der Schilddrüse. Pathologe 24: 357–372
Schmid KW, Farid NR (2006) How to define follicular thyroid carcinoma? Virchows Arch 448: 385–393
Schmid KW (2010) Pathogenese, Klassifikation und Histologie von Schilddrüsenkarzinomen. Onkologe 16:644–656
Schmid KW, Ting S, Sheu SY (2010) Familiäre Karzinome der Schilddrüse. Pathologe 31:485–488
Schmid KW, Reiners C (2011) Wann ist die Feinnadelbiopsie der Schilddrüse am effektivsten? Pathologe 32:169–173
Schwertheim S, Sheu SY, Worm K, et al. (2009) Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 41:475–481
Sheu SY, Schwertheim S, Worm K, et al. (2007) Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 20:779–787
Sheu SY, Grabellus F, Schwertheim S, et al. (2009) Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Horm Metab Res 41: 482–487
Sheu SY, Grabellus F, Schwertheim S, et al. (2010) Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer 102: 376–382
Sheu SY, Schmid KW (2010) Multiple endokrine Neoplasien Typ 2. Pathologe 31:449–454
Sippel RS, Caron NR, Clark OH (2007) An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg 31:924–933
Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell, pp 60–62
Sobrinho-Simões M, Máximo V, Rocha AS, et al. (2008) Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 37:333–362
Stratakis CA, Courcoutsakis NA, Abati A, et al. (1997) Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 82:2037–2043
Ting S, Bockisch A, Führer-Sakel D, Tötsch M, Schmid KW (2012) Feinnadelbiopsie (FNB) der Schilddrüse. Nuklearmediziner, im Druck
Volante M, Collini P, Nikiforov YE, et al. (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256–1264
Volante M, Rapa I, Gandhi M, et al. (2009) RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 94:4735–4741
Vriens MR, Schreinemakers JM, Suh I, et al. (2009) Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol 5:1283–1293
Weber A, Schmid KW, Tannapfel A, Wittekind C (2010) Neuerungen der TNM-Klassifikation der Kopf-Hals-Tumoren. Pathologe 31:339–343
Williams ED (2000) Guest Editorial: Two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181–183
Wittekind C, Greene FL, Henson DE, et al. (2003) TNM Supplement. A commentary on uniform use. 3rd ed. Wiley-Liss, New York, p138
WHO histological classification of thyroid and parathyroid tumours. In: World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs (2004) DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). IARC Press, Lyon, pp49–123
Wollihk N, Schweizer H, Erlic Z, et al. (2010) Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 24:371–387
Xing M (2008) Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41:1135–114
Xu X, Quiros RM, Gattuso P, et al. (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561–4567
Asari R, Koperek O, Scheuba et al. (2009) Follicular thyroid catcinoma in an iodine-repleted endemic goiter region. Ann Surg 249:1023–1031
Bargren AE, Meyer-Rochow GY, Sywak MS et al. (2010) Diagnostic utility of fine needle aspiration cytology in pediatric differentiated thyroid cancer. World J Surg 34:1254–60
Boelaert K (2010) Revised guidelines for the management of thyroid cancer. Nature Reviews Endocrinology 6:185–6
Bonavita JA, Mayo J, Babb J et al. (2009) Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR 193:207–213
Donnellan KA, Carron JD, Bigler SA et al. (2009) Metastatic insulat thyroid carcinoma in the pediatric patient. Head and Neck Medicine and Surgery 30:61–64
Chrishol EJ, Kulinskaya E, Tolley NS (2009) Systemic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscopy 119:1135–1129
Cibas ES, Ali SZ (2009) The Bethesda System for Thyroid Cytopathology. Thyroid 19:1159–65
Cooper DS, Doherty GM, Haugen BR et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Davies L, Welch HG (2010) Thyroid cancer survival in the United States – observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 136(5):440–444
Dralle H, Lorenz K, Machens A (2009) Chirurgie der Schilddrüsenkarzinome. Chirurg 80:1069–1083
Eng CY, Quraishi MS, Bradley PJ (2010) Management of thyroid nodules in adult patients. Head & Neck Oncology 2:11–18
Falvo L, Catania A, A Àndrea V et al. (2004) Prognostic factors of insular versus papillary/follicular thyroid carcinoma. Am Surg 70:461–466
Goretzki PE, Wirowski D, Schwarz K, Pohl P, Böhner H, Starke A, Lammers BJ (2009) Indikation und Durchführung endokrin-chirurgischer Operationen – Bedeutung molekulargenetischer Untersuchungen. Chirurg 80:122–129
Hay ID, Hutchinson ME, Gonzalez-Losada T (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60–year period. Surgery 144:980–988
Hay ID, Gonzalez-Losada T, Reinalda MS et al. (2010) Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34: 1192–1202
Hayashi Y, Lagarde F, Tsuda N et al. (2010) Papillary microcarcinoma of the thyroid among atomic bomb survivors. Cancer 116: 1646–55
Ito Y, Masuoka H, Fukushima M et al. (2008) Differentiation and histologic subgroups influencing the prognosis of papillary thyroid carcinoma. World J Surg 32:1535–43
Ito Y, Miyauchi A, Inoue H et al. (2010) An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34: 28–35
Iyer NG, Shaha AR, Silver CE (2010) Thyroid incidentalomas: treat or not to treat. Eur Arch Otorhinolaryngo 267: 1019–26
Lin X, Zhu B, Liu Y et al. (2010) Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagnostic Pathology 5: 8–14
Lin HW, Bhattacharyya N (2010) Clinical behaviour of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope 120: 712–6
Moon HJ, Kwak JY, Kim MJ et al. (2010) Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 255: 260–8
Morris LGT, Myssiorek D (2010) Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 200: 454–61
Pacini F, Castagna MG, Brilli L et al. (2010) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 5: v214–v219
Piana S, Frasoldati A, Di Felice E et al. (2010) Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868–872
Pisanu A, Chiara BD, Reccia I et al. (2010) Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcome. World J Surg 34: 836–43
Razfari A, Branstetter BF, Christopoulos A et al. (2010) Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 136: 120–5
Sillery JC, Reading CC, Charboneau JW et al. (2010) Thyroid follicular carcinoma: sonographic features of 50 cases. AJR 194: 44–54
Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clinical Oncology 22: 395–404
So YK, Son YI, Hong SD et al. (2010) Subclinical lymph node metastasis in papillary thyroid microcarcinoma : a study of 551 resections. Surgery 148: 526.31
D`Souza MM, Marwahn RK, Sharma R et al. (2010) Prospective evaluation of solitary thyroid nodule on 18 F-FDG PET/CT and high-resolution ultrasonography. Ann Nucl Med 24: 345–55
Sugitani I, Fujimoto Y (2010) Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today 40: 199–215
Volante M, Papotti M (2010) Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. Endocr Pathol 21:1–6
Ward EM, Jemal A, Chen A (2010) Increased incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? Future Oncol 6: 185–8
Bal CS, Kumar A, Pant GS (2004) Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89:1666–1673
Benua RS, Cicale NR, Sonenberg M, Rawson RW (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962:171–182
Benua RS, Leeper RD (1986) A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan G (eds) Frontiers in Thyroidology. Plenum Medical Book, New York, pp 1317–1321
Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM (1998) Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83:4102–4106
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Dietlein M, Dressler J, Eschner W, Grunwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O (2007a) [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)]. Nuklearmedizin 46:213–219
Dietlein M, Dressler J, Eschner W, Grunwald F, Lassmann M, Leisner B, Luster M, Reiners C, Schicha H, Schober O, Deutsche Gesellschaft für Nuklearmedizin, Deutsche Gesellschaft für Medizinische Physik (2007b) [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)]. Nuklearmedizin 46:206–212
Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44:451–456
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892–2899
Edmonds CJ, Hayes S, Kermode JC, Thompson BD (1977) Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 50:799–807
Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A (2007) I-124-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin:121–128
Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA (2007) I-131 activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 92:28–38
Hänscheid H, Lassmann M, Luster M, Kloos R, Reiners C (2009) Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 16:1283–1289
Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:654
Hänscheid H, Verburg FA, Lassmann M, Reiners C (2011) Nachweisgrenzen für Aktivitäten in der Schilddrüsenloge bei der Radioioddiagnostik nach ablativer Therapie. Nuklearmedizin 50:A25
Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885
Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I (2011) Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117(19):4439–46
Jentzen W, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A (2010) The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using I-124 PET(/CT) imaging. Eur J Nucl Med Mol Imaging 37:2298–2306
Krassas GE, Pontikides N (2005) Gonadal effect of radiation from I-131 in male patients with thyroid carcinoma. Arch Androl 51:171–175
Lassmann M, Haenscheid H, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412
Lassmann M, Luster M, Hänscheid H, Reiners C (2004) Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45:619–625
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959
Machens A, Holzhusen HJ, Dralle H (2005) The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysis. Cancer 103:2269–2273
Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428
Medvedec M (2005) Thyroid stunning in vivo and in vitro. Nucl Med Commun 26:731–735
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hänscheid H, Felbinger R, Lassmann M, Reiners C (2006a) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006b) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803
Reiners C (1998) [Sequelae of Czernobyl]. Internist (Berl) 39:592–593
Reiners C, Hänscheid H, Luster M, Lassmann M, Verburg FA (2011) Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 7(10):589–95
Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, Bournaud C, Gupta S, Schlumberger M, Ricard M (2008) I-131 effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445–1450
Rivkees S, Mazzaferri EL, Verburg FA, Reiners C, M.D., Luster M, Breuer CK, Dinauer CA, Udelsman R (2011) Treatment of differentiated thyroid cancer in children. Endocr Rev accepted
Robbins RJ, Schlumberger MJ (2005) The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46:28S–37S
Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457–480
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676
Schlumberger M, Baudin E (1998a) Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249–252
Schlumberger MJ (1998b) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306
Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW (2006) A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878–884
Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM (2004) Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366–1372
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New-York: Wiley-Blackwell, 2009
Tuttle RM, Leboeuf R, Shaha AR (2008) Medical Management of thyroid cancer: a risk adapted approach. J Surg Oncol 97:712–716
Van Nostrand D (2011) Sialoadenitis secondary to (1)(3)(1)I therapy for well-differentiated thyroid cancer. Oral Dis 17:154–161
Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M (2010a) Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37:896–903
Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M (2010b) No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276–283
Biermann M, Pixberg M, Riemann B, Schuck A, Heinecke A, Schmid KW, Willich N, Dralle H, Schober O (2009) Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer – results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin 48: 89–98
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–1214
Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61: 61–74
Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, Carayon P, Ericsson UB, Koutras DA, Lamas de Leon L, DeNayer P, Pacini F, Palumbo G, Santos A, Schlumberger M, Seidel C, Van Herle AJ, de Vijlder JJ (1996) Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity. Ann Biol Clin (Paris) 54:337–342
Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW (2007) Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610–2615
Kloos RT, Mazzaferri EL (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047–5057
Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, Mayr J, Mikosch P, Beheshti M, Lind P (2009) Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging 36:886–893
Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154: 787–803
Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E (2007) Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92:2487–2495
Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T (2009) Impact of 131I SPECT/Spiral CT on nodal staging of differentiated thyroid carcinoma at first radioablation. J Nucl Med 50:18–23
Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M (2010) No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276–283
Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M (2012) Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Hormone Metabolic Research, im Druck
Ben Mrad MD, Gardet P, Roche A et al. (1989) Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer 63:133–138
Bergholm U, Adami HO, Telenius-Berg M, Johansson H, Wilander E (1990) Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncol 29:9–15
Cohen R, Campos JM, Salaun C et al. (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etude des Tumeurs à Calcitonine (GETC). J Clin Endocrinol Metab 85:919–922
Doyle P, Düren C, Nerlich K et al. (2009) Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 94:2970–2974
Dralle H, Scheumann GFW, Hundeshagen H, Massmann J, Pichlmayr R (1992) Die transsternale zervikomediastinale Primärtumorresektion und Lymphadenektomie beim Schilddrüsenkarzinom. Langenbecks Arch Chir 377:34–44
Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112–121
Esik O, Szavcsur P, Szakáll S Jr et al. (2001) Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer 91:2084–2095
Fleming JB, Lee JE, Bouvet M et al. (1999) Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230:697–707
Forrest CH, Frost FA, de Boer WB et al. (1998) Medullary carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology. Cancer 25:295–302
Franc S, Niccoli-Sire P, Cohen R et al. (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol 55:403–409
Gibelin H, Essique D, Jones C, Levillain P, Maréchaud R, Kraimps JL (2005) Increased calcitonin level in thyroid nodules without medullary carcinoma. Br J Surg 92:574–578
Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562–568
Karges W, Dralle H, Raue F et al. (2004) Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58
Leboulleux S, Baudin E, Travagli JP, Schlumberger M (2004) Medullary thyroid carcinoma. Clin Endocrinol 61:299–310
Machens A, Gimm O, Ukkat J, Sutter T, Dralle H (1999) Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma. Langenbecks Arch Surg 384:271–276
Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H (2000a) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915
Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U, Dralle H (2000b) Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbecks Arch Surg 385:398–401
Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H (2001) Thyroid carcinoma invading the cervicovisceral axis: routes of invasion and clinical implications. Surgery 129:23–28
Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28
Machens A, Holzhausen HJ, Lautenschläger C, Thanh PN, Dralle H (2003) Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. A multivariate analysis of clinical risk factors. Cancer 98:712–719
Machens A, Holzhausen HJ, Dralle H (2004a) Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 91:709–712
Machens A, Holzhausen HJ, Dralle H (2004b) Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg 139:43–45
Machens A, Holzhausen HJ, Dralle H (2006) Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: Systemic disease? Surgery 139:28–32
Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:3999–4003
Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591
Machens A, Hoffmann F, Sekulla C, Dralle H (2009) Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 16:1291–1298
Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2665–2663
Moley JF, Dilley WG, DeBenedetti MK (1997) Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225:734–743
Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070–2075
Tung WS, Vesely TM, Moley JF (1995) Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118:1024–1029; discussion 1029–1030
Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044–1049
Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890–901
Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF; GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084
Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132–138
Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH Jr (1980) Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 115:142–148
Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, Macke HR, Paganelli G (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65–71
Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E (1984) Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278–285
Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E, Bombardieri E (2008) MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 52:430–440
Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2002) Complications of neck dissection for thyroid cancer. World J Surg 26:1013–1016
de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466–3469
Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565
Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112–121
Dralle H, Gimm O (1996) Lymphadenektomie beim Schilddrüsencarcinom. Chirurg 67:788–806
Dralle H, Gimm O, Machens A (2001) Sporadic medullary thyroid carcinoma. In: Doherty GM, Skogseid B (eds) Surgical endocrinology. Lippincott Williams & Wilkins, pp 109–126
Dralle H, Machens A, Brauckhoff M, Ukkat J, Sekulla C, Nguyen-Thanh P, Lorenz K, Gimm O (2005) Chirurgie der Schilddrüsenkarzinome. Onkologe 11:58–69
Frank-Raue K, Ziegler R, Raue F (1993) The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res Suppl 27:44–47
Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122:1124–1130/discussion 1130–1131
Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562–567/discussion 567–568
Girelli ME, Dotto S, Nacamulli D et al. (1994) Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 80:113–117
Iwase Y, Maitani Y (2011) Octreotide-Targeted Liposomes Loaded with CPT-11 Enhanced Cytotoxicity for the Treatment of Medullary Thyroid Carcinoma. Mol Pharm (im Druck)
Jackson CE, Talpos GB, Kambouris A, Yott JB, Tashjian AH Jr, Block MA (1983) The clinical course after definitive operation for medullary thyroid carcinoma. Surgery 94:995–1001
Jackson CE, Talpos GB, Block MA, Norum RA, Lloyd RV, Tashjian AH (1984) Clinical value of tumor doubling estimations in multiple endocrine neoplasia type II. Surgery. 96:981–987
Kaczirek K, Schindl M, Weinhausel A, Scheuba C, Passler C, Prager G, raderer M, Hamilton G, Mittlbock M, Siegl V, Pfragner R, Niederle B (2004) Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 89:2397–2401
Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G (2004) Calcitonin measurement to detect medullary thyroid carcinomain nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612
Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F (2010) Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. J Nucl Med 51:624–631
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323–2330
Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246
Machens A, Gimm O, Ukkat J, Sutter T, Dralle H (1999) Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma. Langenbecks Arch Surg. 384:271–276
Machens A, Gimm O, Ukkat J, Hinze R, Schneryer U, Dralle H (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915
Machens A, Hinze R, Thmousch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28
Machens A, Holzhausen HJ, Lautenschlager C, Thanh PN, Dralle H (2003) Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer 98:712–719
Machens A, Holzhausen HJ, Dralle H (2004) Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 91:709–712
Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029–2034
Machens A, Hoffman F, Sekulla C, Dralle H (2009) Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 16:1291–1298
Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663
Mahler C, Verhelst J, Longueville M de, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33:261–269
Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102:175–178
Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Kuma S, Kuma K, Futami H, Yamaguchi K (2000) Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. World J Surg 24:1367–1372
Nguyen TD, Chassard JL, Lagarde P et al. (1992) Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes – the Radiotherapy Cooperative Group. Radiother Oncol 23:1–5
Raue F, Kotzerke J, Reinwein D et al. (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German medullary thyroid carcinoma register. J Clin Invest 71:7–12
Saad MF, Fritsche HA Jr, Samaan NA (1984) Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889–894
Samaan NA, Schultz PN, Hickey RC (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801–805
Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71:363–365
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794–3801
Simpson WJ (1990) Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngol Clin North Am 23:509–521
Skinner MA, Safford SD, Freemerman AJ (2003) RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 23:3601–3606
Stein R, Chen S, Reed L, Richel H, Goldenberg DM (2002) Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 94:51–61
Stein R, Goldenberg DM (2004) A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 3:1559–1564
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767–772
Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff, K, Thanh PN, Dralle H (2004) Multiple endocrine neoplasia 2B sindrome due to codon 918 mutation: clinical manifestation and corse in early and late onset disease. World J Surg 28:1305–1311
Dralle H, Gimm O, Simon D et al. (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744–750/discussion 750–751
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BA, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276:1575–1579
Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, Thanh PN, Frilling A, Klar E, Niederle B, Dralle H (2002) RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2 A syndrome? Surgery 132:952–959
Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003a) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134:42–431
Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H (2003b) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525
Machens A, Ukkat U, Brauckhoff M, Gimm O, Dralle H (2005) Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257:5–59
Machens A, Lorenz K, Dralle H (2009) Individualization of lymph node dissection in RET (Rearranged during Transfection) carriers at risk for medullary thyroid cancer. Ann Surg 250:305–310
Ponder BA, Ponder MA, Coffey R et al. (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397–401
Telander RL, Zimmerman D, Sizemore GW, Heerden JA van, Grant CS (1989) Medullary carcinoma in children. Results of early detection and surgery. Arch Surg 124:84–843
AWMF online – Leitlinie Chirurgie/Onkologie: Maligne Schilddrüsentumoren: http://www.uni-duesseldorf.de/AWMF/ll/032-014.htm
Baum RP, Hofmann M (2004) Nuklearmedizinische Diagnostik neuroendokriner Tumoren. Onkologe 10:598–610
Baum RP, Söldner J, Schmücking M, Niesen A (2004) Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren. Onkologe 10:1098–1110
Brückel J, Kotzerke J, Reske SN, Dralle H, Böhm BO (2001) Lokalisation von Lymphknotenfiliae bei persistierendem medullären Schilddrüsenkarzinom mit 18 F-DOPA-Positronen-Emissions-Tomographie. Tumordiagn u Ther 22:121–125
Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R, Bulkley GB (1998) Effectivie long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 227:887–895
Dottorini ME, assi A, Sironi M (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathological variables. Cancer 77:1556–1565
Dralle H (2002) Lymph node dissection and medullary thyroid carcinoma. Br J Surg 89:1073–1075
Dralle H, Machens A, Brauckhoff M, Ukkat J, Sekulla C, Nguyen-Thanh P, Lorenz K, Gimm O (2005) Chirurgie der Schilddrüsenkarzinome. Onkologe 11:58–69
Esik O, Tusnady G, Tron L, Boer A, Szentirmay Z, Szablocs I, Racz K, Lengyel E, Szekely J, Kasler M (2002) Markov model-based estimation of individual survival probability for medullary thyroid cancer patients. Pathol Oncol Res 8: 3–104
Frank-Raue K, Raue F, Buhr HJ (1992) Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterisation. Thyroid 2:113–117
Gautvik KM, Talle K, Hager B (1989) Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer 63:175–180
Machens A, Gimm O, Ukkat J, Sutter T, Dralle H (1999) Repeat mediastinal lymph node dissection for palliation in advanced medullary thyroid carcinoma. Langenbeck’s Arch Surg 384:271–286
Machens A, Hinze R, Dralle H (2001a) Surgery on the cervicovisceral axis for invasive thyroid cancer. Langenbeck’s Arch Surg 386:318–323
Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H (2001b) Thyroid carcinoma invading the cervicovisceral axis: routes of invasin and clinical implications. Surgery 129:23–28
Machens A, Holzhausen HJ, Dralle H (2004) Prediction of mediastinal lymph node metastasis in medullary thyrid carcinoma. Br J Surg 91:709–712
Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endcrinol Metab 90:2029–2034
Mann K, Möller LC, Bockisch A, Quadbeck B, Schmid KW, Janssen OE (2005) Chemotherapie beim Schilddrüsenkarzinom. Onkologe 11:78–86
Mirallie E, Vuilez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F (2005) High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779–788
Miyuachi A Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023–1028
Miyauchi A, Matsuzuka F, Kuma K (1988) Evaluation of surgical results and prediction of prognostic in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels. World J Surg 12:610–615
Mrad Ben MD, Gardet P, Roche A (1989) Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer 63:133–138
Pellegriti G, Leboulieux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:153 –1542
Schuck A, Biermann M, Schober O, Willich N (2005) Strahlentherapie des Schilddrüsenkarzinoms. Onkologe 11:87–92
Szavcsur P, Gödeny M, Bajzik G, Lengyel E, Repa I, Tron L, Boer A, Vincze B, Poti Z, Szabolcs I, Esik O (2005) Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. EJSO 31:183–190
Tisell L, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66
Tung WS, Vesely TM, Moley JF (1995) Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118:1024–1030
van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395–401
Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21(2):125–34
Agrawal S, Rao RS, Parikh DM, Parikh HK, Borges AM, Sampat MB (1996) Histologic trends in thyroid cancer 1969–1993: a clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid. J Surg Oncol 63(4):251–5
Auersperg M, Us-Krasovec M, Petric G, Pogacnik A, Besic N (1990) Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 102(9):267–70
Bakiri F, Djemli FK, Mokrane LA, Djidel FK (1998) The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma Cancer 82(6):1146–53
Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M (2005) Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 390(3):203–8
Besic N, Hocevar M, Zgajnar J (2010) Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid 20(6):623–6
Carcangiu ML, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83(2):135–58
De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, Schlumberger M (2004) Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractiontated accelerated external radiotherapy. Int J Radiation Oncology Biol Phys 60:1137–1143
Demeter JG, De Jong SA, Lawrence AM, Paloyan E (1991) Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 110(6):956–61
Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC (2011) Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21(1):25–30
Goutsouliak V, Hay JH (2005) Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study. Clin Oncol (R Coll Radiol) 17(2):75–8
Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20(9):975–80
Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7–14
Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A (2004) Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89(12):6139–45
Junor EJ, Paul J, Reed NS (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18(2):83–8
Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T, Ando Y (2010) The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40(6):596–9
Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330–5
Levendag PC, De Porre PM, van Putten WL (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26(1):125–8
McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130(6):1028–34
Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P (2007) New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg 392(4):397–404
Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC (2009) A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3):233–40
Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25–year period. World J Surg 22(7):725–30
Orita Y, Sugitani I, Amemiya T, Fujimoto Y (2011) Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery 150(6):1212–9
Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 384(3):284–93
Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9(1):57–64
Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M (2010) 18 F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging ;37(12):2277–85
Schmid KW (2010) Molekularpathologie von Schilddrüsentumoren [Molecular pathology of thyroid tumors]. Pathologe Suppl 2:229–33
Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. Mar;16(1):17–44
Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, Iwasaki H, Ito K (2002) The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131(3):245–8
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25(5):617–22
Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC (2009) Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol 92(1):100–4
Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M (2010) High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 95(9):E54–7
Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L (1996) Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 40(5):953–8
Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA (1990) Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66(2):321–30
WHO histological classification of thyroid and parathyroid tumours (2004) In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (Hrsg) World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs IARC, Lyon, S 49–123
Woyach JA, Shah MH (2009) New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16(3):715–31
Aihira H, Tsutsumi Y, Ishikawa H (1992) Extramedullary plasmacytoma of the thyroid associated with follicular colonization and stromal deposition of polytypic immunoglobulins and major histocompatibility antigens. Acta Cytopathol Jpn 42:672–682
Al-Shobi S, Novosolov F, Sabanci U, Epstein HE, Greenspan FS, Clark OH (1997) Management of thyroid carcinosarcoma. Surgery 122:548–552
Aozasa K, Inoue A, Yoshimura H et al. (1986) Plasmacytoma of the thyroid gland. Cancer 58:105–112
Bhandarkar ND, Chan J, Strime M (2005) A rare case of mucoepidermoid carcinoma of the thyroid. Am J Otolaryngol 26:138–141
Beguin Y, Boniver J, Bury J et al. (1987) Plasmacytoma of the thyroid: a case report with use of the immunoperoxidase technique and a review of the literature. Surgery 101:496–500
Belal AB, Ayman A, Kandil A et al. (2001) Primary thyroid lymphoma: a retrospective analysis of prognostic factors. Am J Clin Oncol 24:299–305
Benoit L, Favoulet P, Arnould L, Margarot A, Franceschini C, Collin F, Fraisse J, Cuisenier J, Cougard P (2004) Metastatic renal cell carcinoma to the thyroid gland. Ann Chir 129:218–223
Berge T, Lundberg S (1977) Cancer in Malmo 1958–1969. An autopsy study. Acta Pathol Microbiol Scand (suppl) 260:1–235
Blaloch ZN, Sack MJ, Yu GH, Gupta PK (1999) Papillary formation in metastatic melanoma. Diagn Cytopathol 20:148–151
Brady LW, O’Neill EA, Farber SH (1977) Unusual sites of metastases. Semin Oncol 4:59–64
Bronner MP, LiVolsi VA, Jennings TA (1988) PLAT: paraganglioma like adenomas of the thyroid. Surg Pathol 1:383–390
Burton GV, Altwater S, Borowitz MJ, Huang AT (1990) Extranodal head and neck lymphomas: prognosis and patterns of recurrence. Arch Otolaryngol Head Neck Surg 116:69–73
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee of Hodgkin’s disease staging classification. Cancer Res 31:1860–1861
Chan JKC, Rosai J (1991) Tumors of the neck showing thymic or related branchial pouch differentiation a unifying concept. Hum Pathol 22:349–367
Compagno J, Oertel JE (1980) Malignant lymphoma and other lymphoproliferative disorders of the thyroid gland: a clinicopathological study of 245 cases. Am J Clin Pathol 74:1–8
Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. (2000) Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000 May;24(5):623–39
Doria R, Jekel JF, Cooper DL (1994) Thyroid lymphoma. The case for combined modality therapy. Cancer 73:200–206
Duggal NM, Horattas MC (2008) Metastatic renal cell carcinoma to the thyroid gland. Endocr Pract 14:1040–6
Erkilic S, Erkilic A, Bayazit YA (2003) Primary leiomyoma of the thyroid gland. J Laryngol Otol 117:832–834
Erickson ML, Tapia B, Moreno ER, McKee MA, Kowalski DP, Reyes-Mugia M (2005) Early metastasizing SETTLE of the thyroid. Ped Develop Pathol 8:599–606
Eusebi V, Carcangiu ML, Dina R, Rosai J (1990) Keratin-positive epitheloid angiosarcoma of the thyroid. A report of four cases. Am J Surg Pathol 14:737–747
Ferri E, Manconi R, Armato E, Ianniello F. Primary paraganglioma of thyroid gland: a clinicopathologic and immunohistochemical study with review of the literature. (2009) Acta Otorhinolaryngol Ital 29:97–102
Filho Magnata LA, Bordallo MA, Pessoa CH, Corbo R, Bulzico DA, Dias FL, Machado AL, Soares AB, Ferman S (2010) Thyroid spindle epithelial tumor with thymus-like differentiation (SETTLE): case report and review. Arq Bras Endocrinol Metabol 54:657–62
Fontenot JW, Levine SN, Adegboyega PA, Cotelingam JD (2008) Plasma cell granuloma of the thyroid: report of case and review of literature. Endocr Pract 14:611–7
Friedberg MH, Coburn MC, Monchik JM (1994) Role of surgery in stage IE non-Hodgkin‘s lymphoma of the thyroid. Surgery 116:1061–1067
Galieni P, Cavo M, Pulsoni A et al. (2000) Clinical outcome of extramedullary plasmacytoma. Haematologica 85:47–51
Ge Y, Luna MA, Cowan DF, Truong LD, Ayala AG. (2009) Thyrolipoma and thyrolipomatosis: 5 case reports and historical review of the literature. Ann Diagn Pathol 13:384–9
Goumoens E von (1968) Sekundäre Geschwülste der Schilddrüse. Schweiz Med Wochenschr 98:19–25
Gutzeit A, Stuckmann G, Tosoni I, Erdin D, Binkert CA. (2011) A cavernous hemangioma of the thyroid gland: First documentation by ultrasound of a rare pathology. J Clin Ultrasound 39:172–4
Hamburger JI, Miller JM, Kini SR (1983) Lymphoma of the thyroid. Ann Intern Med 99:685–690
Hansen T, Gaumann A, Ghalibafian M, Höferlin A, Heintz A, Kirkpatrick CJ. (2004) Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease. Virchows Arch 445:315–9
Haugen BR, Nawaz S, Cohn A, Shryder K, Bunn PA, Liechty DR, Ridgeway EC (1994) Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid 4:297–300
Heffess CS, Wenig BM, Thompson LD (2002) Metastatic renal cell carcinoma to the thyroid gland. Cancer 95:1869–1878
Hess W (1854) Beitrag zur Casuistik der Geschwülste mit zeugungsähnlichem Inhalte. Inauguraldissertation, Gießen
Huang GW, Li YX, Hu ZL. (2009) Primary myxoid liposarcoma of the thyroid gland. J Clin Pathol 62:1037–8
Hull OF (1955) Critical analysis of 221 thyroid glands: study of thyroid glands obtained at necropsy in Colorado. Arch Pathol 59:291–335
Hyjek E, Isaacson PG (1988) Primary B-cell lymphoma of the thyroid and its relationship to Hashimoto‘s thyroiditis. Hum Pathol 19:1315–1326
Isaacson PG (1995) The Malt lymphoma concept updated. Ann Oncol 6:319–320
Jonak C, Troch M, Müllauer L et al. (2010) Ritumximab plus dose-reduced Cyclophosphamide, Metoxantrone, Vincristine and Prednisolone are effective in elderly patients with diffuse large-cell B-cell lymphomas of the thyroid. Thyroid 20:193 –195
Kleer CG, Giordano TJ, Merino MJ et al. (2000) Squamous cell carinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma. Mod Pathol 13:742–746
Kim TY, Kim WB, Gong G, Hong SJ, Shong YK (2005) Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol Oxf 62:236–241
Kitagawa W, Kameyama K, Tamai S, Shimizu K, Ito K, Akasu H (2004) Adenolipoma of the thyroid gland. Surg Today 34:593–596
Kumar R, Gupta R, Khullar S, Dasan B, Malhorta A (2000) Thyroid hemangioma. Clin Nucl Med 10:769–771
Ladurner D, Toesch M, Lutze T, Bangerl I, Sanbichler P, Schmid KW (1990) Das maligne Hämangioendotheliom der Schilddrüse. Pathologie, Klinik und Prognose. Wien Klin Wochenschr 102:256–259
Lam KY, Lo CY (1998) Metastatic tumors of the thyroid gland: a study of 79 cases in chinese patients. Arch Pathol Lab Med 122:37–41
Lamovec J, Zidar A, Zidanik B (1994) Epitheloid angiosarcomas of the thyroid gland. Report of two cases. Arch Pathol Lab Med 118:642–646
Lesalnieks I, Winter H, Bareck E, Sotiropoulos GC, Goretzki PE, Klinkhammer-Schalke M, Bröckner S, Trupka A, Anthuber M, Rupprecht H, Raab M, Meyer W, Reichmann F, Kästel M, Mayr M, Braun W, Schlitt HJ, Agha A. (2008) Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival. Thyroid 18:615 – 24
Limacher F (1898) Über Blutgefäßendotheliome der Struma mit einem Anhang über Knochenmetastasen bei Struma maligna. In: Virchow R (Hrsg) Beiträge zur Geschwulstlehre. Arch Pathol Anat Physiol Klin Med (Suppl) 151:113–150
Machens A, Dralle H Outcome after thyroid surgery for metastasis from renal cell cancer (2010) Surgery 147:65–71
Maiorana A, Collina G, Cesinaro AM, Fano RA, Eusebi V (1996) Epitheloid angiosarcoma of the thyroid. Virchows Arch 429:131–137
McCabe DP, Farrar WB, Petkov TM, Finkelmeyer W, O’Dwyer P, James A (1985) Clinical and pathological correlations in diseases metastatic to the thyroid gland. Am J Surg 150:519–523
Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, Rossi A, Oldani E, Federico M, Luminari S, Bellei M, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Lopez-Guillermo A, Busetto M, Cavalli F, Zucca E, Cortelazzo S. (2011) High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leuk Lymphoma 52:823–32
Mirallié E, Rigaud J, Mathonnet M, Gibelin H, Regenet N, Hamy A, Bretagnol F, de Calan L, Le Néel JC, Kraimps JL (2005) Management and prognosis of metastases to the thyroid gland. J Am Coll Surg 200: 203 – 207
Miiji LO, Nguyen GK (2005) Metastatic melanoma of the thyroid mimicking a papillary carcinoma on fine needle aspiration. Diagn Cytopathol 32:374–376
Mitra A, Fisher C, Rhys-Evans P, Harmer C (2004) Liposarcoma of the thyroid. Sarcoma 8:91–6
Mitsudo SM, Grajower MM, Balbi H et al. (1987) Malignant paraganglioma of the thyroid gland. Arch Pathol Lab Med 111:378–381
Morgen EK, Geddie W, Boerner S, Bailey D, Santos Gda C. (2010) The role of fine-needle aspiration in the diagnosis of thyroid lymphoma: a retrospective study of nine cases and review of published series. J Clin Pathol 63:129–33
Mortensen JD, Woolner LB, Bennett Wa (1956) Secondary malignant tumory of the thyroid gland. Cancer 9:306–310
Nakhjavani MK, Gharib H, Goellner JR, Heerden JA van (1997) Metastasis to the thyroid gland. A report of 43 cases. Cancer 79:574–578
Nielsen VT, Knudsen N, Holm IE (1986) Liposarcoma of the thyroid gland. Tumori 72:499–502
Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, Atasoy BM, Igdem S, Ozsahin M, Ozyar E. (2010) Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. Ann Oncol 22:156–64
Papotti M, Arrondini M, Tavaglione V, Veltri A, Volante M (2008) Diagnostic controversies in vascular proliferations of the thyroid gland. Endocr Pathol 19:175–83
Pupovac D (1896) Ein Fall von Teratoma Colli mit Veränderungen in den regionären Lymphdrüsen. Arch Klin Chir 53:59–67
Pyke CM, Grantt CS, Habermann TM et al. (1992) Non-Hodgkin’s lymphoma of the thyroid: is more than biopsy necessary? World J Surg 16:604–608
Riedlinger WF, Lack EE, Robson CD, Rahbar R, Nosé V (2005) Primary thyroid teratomas in children: a report of 11 cases with a proposal of criteria for their diagnosis. Am J Surg Pathol 29:700–6
Rosa M, Toronczyk K (2010) Fine needle aspiration biopsy of three cases of squamous cell carcinoma presenting as a thyroid mass: cytological findings and differential diagnosis. Cytopathology. 28 Epub ahead of print
Rhatigan RM, Roque JL, Bucher RL (1977) Mucoepidermoid carcinoma of the thyroid gland. Cancer 39:210–249
Rhomberg W, Boehler E, Eiter H, Fritzsche H, Breitfellner G (2004) Treatment options for malignant haemangioendothelioma of the thyroid. In J Radiat Oncol Biol Phys 60:401–405
Saltykow S (1905) Über das gleichzeitige Vorkommen des Sarkoms und des Carcinomas in der Schilddrüse. Zentralbl Allg Pathol 12:561–570
Santeusanio G, Schiaroli S, Ortenzi A, Mulè A, Perrone G, Fadda G. (2008) Solitary fibrous tumour of thyroid: report of two cases with immunohistochemical features and literature review. Head Neck Pathol 2:231–5
Sarinah B, Hisham AN (2010) Primary lymphoma of the thyroid: diagnostic and therapeutic considerations. Asian J Surg 33:20–4
Schröder S, Bürck CD, Heer K de (1987) Metastasen in der Schilddrüse – Morphologie und Klinik von 25 sekundären Schilddrüsengeschwülsten. Langenbecks Arch Chir 370:25–35
Sheu SY, Grabellus F, Schwertheim S, Mann K, Ensinger C, Ofner D, Bockhorn M, Fuhrer D, Schmid KW (2009) COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option? Horm Metab Res 41:314–9
Shimaoka K, Sokal JE, Pickren JW (1962) Metastatic neoplasms in the thyroid gland: pathological and clinical findings. Cancer 15:557–562
Silverberg SG, Vidone RA (1966) Metastatic tumors in the thyroid. Pacific Med Surg 74:175–185
Skarsgard ED, Connors JM, Robins RE (1991) A current analysis of primary lymphoma of the thyroid. Arch Surg 126:1199–1204
Steele SR, Royer M, Brown TA et al. (2001) Mucoepidermoid carcinoma of the thyroid gland: suggested surgical approach. Am J Otolaryngol Head Neck Med Surg 26:138–141
Takayama F, Takashima S, Mastuba H, Kobayashi S, Ito N, Sone S (2001) MR imaging of primary leiomyosarcoma of the thyroid gland. Eur J Radiol 37:36–41
Thieblemont C, Mayer A, Dumonet C et al. (2002) Primary thyroid lymphoma is a heterogenous disease. J Clin Endocrinol Metab 87:105–111
Thompson LDR, Wenig BM, Adair CF, Heffess CS (1996) Peripheral Nerve Sheath tumors of the thyroid gland: a series of four cases and a review of the literature. Endocr Pathol 7:309–318
Thompson LDR, Wenig BM, Adair CF, Shmookler BM, Heffess CS (1997) Primary smooth muscle tumors of the thyroid gland. Cancer 79:579–587
Tsang RW, Brierlev JD, Asa SL, Sturgeon JF (2003) Malignant teratoma of the thyroid: Aggressive chemoradiation therapy is required after surgery. Thyroid 13:401–404
Wada N, Hirakawa S, Rino Y, Hasuo K, Kawachi K, Nakatani Y, Inui K, Takanashi Y. (2005) Solitary metachronous metastasis to the thyroid from renal clear cell carcinoma 19 years after nephrectomy. Surg Today 35:483–487
Wang TS, Ocal IT, Oxley K, Sosa JA (2008) Primary leiomyosarcoma of the thyroid gland. Thyroid 18:425–8
Widder S, Pasieka JL (2004) Primary thyroid lymphomas. Curr Treat Opin Oncol 5:301–313
Willis RA (1931) Metastatic tumors in the thyroid gland. Am J Pathol 7:187–208
Zhou XH (2002) Primary squamous cell carcinoma of the thyroid. EJSO 28:42–45
Amino N, Mori H, Iwatani Y et al. (1982) High prevalence of transient postpartum thyrotoxicosis and hypothyroidism. N Engl J Med 306:849–852
Badenhoop K, Schwarz G, Walfish PG et al. (1990) Susceptibility to thyroid autoimmune disease: molecular analysis of HLA-D region genes identifies new markers for goitrous Hashimoto's thyroiditis. J Clin Endocrinol Metab 71:1131–1137
Berger SA, Zonzein J, Villamena P, Mittman N (1983) Infectious diseases of the thyroid gland. Rev Infect Dis 5:108–122
Brander A (1992) Ultrasound appearances in de Quervain's subacute thyroiditis with longterm follow-up. J Intern Med 232:321–325
Bruin TWA de, Rieckhoff FPM, DeBoer JJ (1990) An outbreak of thyrotoxicosis due to atypical subacute thyroiditis. J Clin Endocrinol Metab 70:396–402
Dayan CM, Daniels GH (1996) Chronic autoimmune thyroiditis. N Engl J Med 335:99–107
DeGroot LJ, Quintans J (1990) The causes of autoimmune thyroid disease. Endocr Rev 10:537–562
Desailloud R, Hober D (2009) Viruses and thyroiditis: an update. Virol J 12:6:5
Duntas LH (2010) Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 95:5180–5188
Erdem N, Erdogan M, Ozbek M, Karadeniz M, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C, Tuzun M, Kabalak TJ (2007) Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. Endocrinol Invest 30:546–550
Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ (2003) Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 88:2100–2105
Feldkamp J (2009) Autoimmunthyreoiditis. Diagnose und Therapie. Dtsch Med Wochenschr 134:2504–2509
Glinoer D, Riahi M, Grün JP (1994) Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. J Clin Endocrinol Metab 79:197–204
Gutekunst R, Hafermann W, Mansky T, Scriba PC (1989) Ultrasonography related to clinical and laboratory findings in lymphocytic thyroiditis. Acta Endocrinol 121:129–135
Hay ID (1985) Thyroiditis: a clinical update. Mayo Clin Proc 60:836–843
Heller J, Musiolik J, Homrighausen A, Sauerbruch T, Spengler U (1996) Vorkommen und Bedeutung von Autoantikörpern im Rahmen der Interferontherapie der chronischen Hepatitis C. Dtsch Med Wochenschr 121:1179–1183
Heufelder A, Hay ID (1994) Evidence for autoimmune mechanisms in the evolution of invasive fibrous thyroiditis (Riedel's struma). J Clin Invest 72:788–793
Hollowell JG, Staehling NW, Flanders D et al. (2002) Serum TSH, T4, and Thyroid Autoantibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499
Klein I, Levey GS (1982) Silent thyrotoxic thyroiditis. Ann Intern Med 96:242–244
Lazarus JH (2005) Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. Treat Endocrinol 4(1):31–41. Review
Lio S, Pontocorvi A, Caruso M et al. (1984) Transitory subclinical and permanent hypothyroidism in the course of subacute thyroiditis (de Quervain). Acta Endocrinol 106:67–70
Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al.(1996) Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-1-therapy. Clin Endocrinol (Oxf) 44:635–642
Mittra ES, McDougall IR (2007) Recurrent silent thyroiditis: a report of four patients and review of the literature. Thyroid 17:671–675
Masuoka H, Miyauchi A, Tomoda C, Inoue H, Takamura Y, Ito Y, Kobayashi K, Miya A (2011) Imaging studies in sixty patients with acute suppurative thyroiditis. Thyroid 21:1075–1080
Nikolai TF, Coombs GJ, McKenzie AK et al. (1982) Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Int Med 142:2281–2283
Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A (2008) Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 47:725–729
Othman S, Phillips DI, Parkes AB et al. (1990) A long-term follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 32:559–564
Paes JE, Burman KD, Cohen J, Franklyn J, McHenry CR, Shoham S, Kloos RT (2010) Acute bacterial suppurative thyroiditis: a clinical review and expert opinion. Thyroid 20:247–255
Peter SA (1992) Painful subacute thyroiditis (de Quervain's thyroiditis). J Natl Med Assoc 84:877–879
Quaratino S, Badami E, Pang YY et al. (2004) Degenerative self-reactive human T-cell receptor causes spontaneous autoimmune disease in mice. Nat Med 10:929–926
Rapoport B (1991) Pathophysiology of Hashimoto's thyroiditis and hypothyroidism. Ann Rev Med 42:91–96
Scherbaum WA, Paschke R (1995) Bedeutung der Schilddrüsenantikörper für Diagnostik und Verlaufsbeurteilung von Schilddrüsenerkrankungen. Internist 36:303–309
Schott M, Scherbaum WA, Morgenthaler NG (2005) TSH-receptor autoantibodies in Graves’ disease. Trends Endocrinol Metab 6:243–248
Szabo SM, Allen DB (1989) Thyroiditis. Differentiation of acute suppurative and subacute. Case report and review of the literature. Clin Pediatr 28:171–174
Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T (1990) Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto's thyroiditis. Lancet 336:1084–1086
Tomer Y, Davies TF (1993) Infection, thyroid disease, and autoimmunity. Endocr Rev 14:107–120
Tunbridge WM, Brewis M, French JM et al. (1981) Natural history of autoimmune thyroiditis. BMJ 282:258–262
Volpé R (1993) The management of subacute (de Quervain's) thyroiditis. Thyroid 3:253–255
Bogazzi F, Bartalena L, Martino E (2010) Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 95(6):2529–35
Diggins B, Diaz-Cano SJ, Schulte KM (submitted) Campylobacter jejuni as a Cause of Acute Suppurative Thyroiditis, on a Background of SLE-related End Stage Renal Failure and CMV viraemia: A Case Report and Review of the Literature Thyroid
Duininck TM, van Heerden JA, Fatourechi V, Curlee KJ, Farley DR, Thompson GB, Grant CS, Lloyd RV (2002) de Quervain's thyroiditis: surgical experience. Endocr Pract 8:255–258
Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA (2009) Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery 146(6):1105–15
McManus C, Luo J, Sippel R, Chen H (2011) Should Patients with Symptomatic Hashimoto's Thyroiditis Pursue Surgery? J Surg Res. Feb 20. [Epub ahead of print]
Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR (1995) Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, white and African. Cancer 76:2312–2318
Paes JE, Burman KD, Cohen J, Franklyn J, McHenry CR, Shoham S, Kloos RT (2010) Acute bacterial suppurative thyroiditis: A clinical review and expert opinion. Thyroid 20(3):247–255
Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E, Clark OH, Duh QY (2008) Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid 18(7):729–34
Takami H, Kozokai M (1994) Tuberculous thyroiditis: report of a case with a review of the literature. Endocr J 41:743–747
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Feldkamp, J. et al. (2013). Schilddrüse. In: Siewert, J., Rothmund, M., Schumpelick, V. (eds) Praxis der Viszeralchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-14285-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-14285-7_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-14284-0
Online ISBN: 978-3-642-14285-7
eBook Packages: Medicine (German Language)